Antibody-drug conjugates

HK40137389APending Publication Date: 2026-09-11ADC THERAPEUTICS SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124965
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-17
Filing Date
2026-06-17
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure relates to a drug-linking subsystem for an antibody-drug conjugate and an antibody-drug conjugate comprising the same.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of antibody-drug conjugates, and more specifically, to antibody-drug conjugates having polyglycine linkers. Background Technology

[0002] Antibody-drug conjugates (ADCs) are essentially targeted deliverables of active drugs to selected specific cellular sites. They are an effective method for treating a variety of diseases and offer many advantages over systemic delivery of the same drug.

[0003] In the field of ADCs (Advanced Drug Acquisition Combination Therapy), chemical linkers are typically used to connect drugs to antibodies. These linkers need to possess several key properties, including the requirement that they remain stable in plasma for an extended period after drug administration. Stable linkers enable the ADC to be localized to the intended site or cells in the body and prevent premature release of the payload in circulation, which could indiscriminately induce a variety of undesirable biological responses, thereby reducing the therapeutic index of the ADC. After internalization, the ADC should be processed to efficiently release the payload so that it can bind to its target. Summary of the Invention

[0004] The inventors of this case have surprisingly discovered that linkers with a polyglycine system are well-suited for metal-free click-reactive chemistry or thiol conjugation, or transglutaminase-mediated transamidation, to conjugate drug payloads with antibodies, thereby producing antibody-drug conjugates that show no or negligible aggregation tendency. The resulting ADCs exhibited significant in vivo efficacy. Therefore, the inventors have, for the first time, been able to prepare an ADC with a payload that exhibits efficacy on the same order of magnitude as the most potent antibody-drug conjugates known to date, particularly the antibody-exatecan conjugate, while showing absolutely no aggregation. Furthermore, the resulting ADCs showed improved conjugation efficiency.

[0005] The present invention relates firstly and most importantly to an antibody-drug conjugate having structure (1). (1)

[0007] in: AB is a cell-binding agent, such as an antibody; n is an integer in the range of 5 to 8; L 1 For connectors; L 2 For connectors; L 3 For connectors; a, b, and c are independently 0 or 1; Z is a linker group obtained by metal-free click reaction, thiol bonding, or transglutaminase-mediated transamidation. Or Z is absent, where a and b are 0, and the N-terminus of polyglycine is directly bonded to AB in the absence of a sorting enzyme recognition sequence motif; D represents the effective drug load; x is an integer in the range of 1 to 8.

[0008] The present invention further relates to methods for synthesizing antibody-drug conjugates according to the invention, linker-drug constructs suitable for use in methods according to the invention, medical uses of antibody-drug conjugates according to the invention, and pharmaceutical compositions comprising antibody-drug conjugates according to the invention. Detailed Implementation

[0009] definition

[0010] As used in this specification and the claims, the verb "to comprise" and its variations are used in their non-limiting sense to mean that the items following the word are included, but not excluding items not specifically mentioned. Furthermore, reference to an element by the indefinite articles "a" or "an" does not preclude the possibility of more than one of the elements, unless the context explicitly requires the presence of exactly one element. The indefinite articles "a" or "an" therefore generally mean "at least one."

[0011] The compounds disclosed in this specification and claims may contain one or more asymmetric centers, and the compounds may exist in different diastereomers and / or enantiomers. Unless otherwise stated, the description of any compound in this specification and claims is intended to include all diastereomers and mixtures thereof. Additionally, unless otherwise stated, the description of any compound in this specification and claims is intended to include individual enantiomers, as well as any mixture of enantiomers (racemic or other forms). When the structure of a compound is described as a specific enantiomer, it should be understood that the invention of this application is not limited to that specific enantiomer.

[0012] Compounds can exist in different tautomer forms. Unless otherwise stated, compounds according to the present invention are intended to include all tautomer forms. When the structure of a compound is described as a specific tautomer, it should be understood that the invention of this application is not limited to that specific tautomer.

[0013] The compounds disclosed in this specification and claims may further exist as R and S stereoisomers. Unless otherwise stated, the description of any compound in this specification and claims is intended to include both the individual R stereoisomer and the individual S stereoisomer, as well as mixtures thereof. When the structure of a compound is described as a specific S or R stereoisomer, it should be understood that the invention of this application is not limited to that specific S or R stereoisomer.

[0014] The compounds disclosed in this specification and claims may further exist in the form of exo- and endo-diasteremeric forms. Unless otherwise stated, the description of any compound in this specification and claims is intended to include individual exo- and endo-diasteremeric forms of the compound, as well as mixtures thereof. When the structure of a compound is described as a particular endo- or exo-diasteremeric form, it should be understood that the invention of this application is not limited to that particular endo- or exo-diasteremeric form.

[0015] Compounds according to the invention can exist in salt form, which is also covered by the invention. Salts are generally pharmaceutically acceptable salts containing pharmaceutically acceptable anions. The term "its salt" means a compound formed when an acidic proton (typically a proton of an acid) is replaced by a cation (such as a metal cation or an organic cation). Where applicable, the salt is pharmaceutically acceptable, but this is not necessary for salts not intended for administration to a patient. For example, in the salt of a compound, the compound can be protonated by an inorganic or organic acid to form a cation, wherein the conjugate base of the inorganic or organic acid serves as the anionic component of the salt.

[0016] The term "pharmaceutically acceptable salt" means a salt that is acceptable for administration to patients (e.g., mammals) (a salt containing an anti-ion that has acceptable mammalian safety for a given dosing regimen). Such salts can be derived from pharmaceutically acceptable inorganic or organic bases and from pharmaceutically acceptable inorganic or organic acids. "Pharmaceutically acceptable salt" refers to a pharmaceutically acceptable salt of a compound derived from a variety of organic and inorganic anti-ions known in the art, and includes, for example, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, etc.; and when the molecule contains a basic functional group, salts of organic or inorganic acids, such as hydrochlorides, hydrobromides, formates, tartrates, benzenesulfonates, methanesulfonates, acetates, maleates, oxalates, etc.

[0017] The term "protein" is used in its normal scientific sense in this article. In this article, a polypeptide containing approximately 10 or more amino acids is considered a protein. Proteins may contain natural amino acids, but they may also contain non-natural amino acids.

[0018] The term "antibody" is used herein in its normal scientific sense. An antibody is a protein produced by the immune system that recognizes and binds to a specific antigen. Antibodies are examples of glycoproteins. The term "antibody" is used herein in its broadest sense and specifically includes monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), antibody fragments, and double-chain and single-chain antibodies. The term "antibody" also refers herein to human antibodies, humanized antibodies, chimeric antibodies, and antibodies that specifically bind to cancer antigens. The term "antibody" refers to the entire immunoglobulin, but also includes resistant-binding fragments of antibodies. Furthermore, the term includes genetically engineered antibodies and antibody derivatives. Antibodies, antibody fragments, and genetically engineered antibodies can be obtained by methods known in the art.

[0019] An “antibody fragment” is defined herein as a portion of a complete antibody containing its antigen-binding region or variable region. Examples of antibody fragments include Fab, Fab', F(ab')2 and Fv fragments, biantibodies, microantibodies, triantibodies, tetraantibodies, linear antibodies, single-chain antibody molecules, scFv, scFv-Fc, multispecific antibody fragments formed from antibody fragments, fragments generated from Fab expression libraries, or epitope-binding fragments of any of the above antibodies that are immune-specifically bound to a target antigen (e.g., cancer cell antigen, viral antigen, or microbial antigen).

[0020] In this paper, “antigen” is defined as an entity that an antibody specifically binds to.

[0021] The terms "specific binding" and "specifically binds" are defined herein as a highly selective manner in which an antibody or antibody binds to a corresponding epitope of its target antigen without binding to numerous other antigens. Typically, the binding affinity of the antibody or antibody derivative is at least about 1 × 10⁻⁶. -7 M, preferred 10 -8 M to 10 -9 M, 10 -10 M, 10 -11 M or 10 -12 M, and its binding affinity to the predetermined antigen is at least twice that to non-specific antigens (e.g., BSA, casein) other than the predetermined antigen or closely related antigens.

[0022] The term “substantial” or “substantially” is defined herein as a majority of a mixture or sample, i.e., >50%, preferably a group greater than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

[0023] A “linker” is defined herein as a portion of a compound that links two or more elements. For example, in an antibody-conjugate, the antibody and the payload are covalently linked to each other via a linker. A linker may comprise one or more linkers and spacer portions connecting the various portions within the linkers.

[0024] A “spacer” or “spacer part” is defined herein as a part that separates (i.e., distances between) two (or more) parts of a connector and covalently links them together. A connector can be, for example, part of a connector-construction, connector-conjugate, or bioconjugate, as defined below.

[0025] The “self-sacrificing group” is defined in this paper as part of the linker in an antibody-drug conjugate, which functions to conditionally release the free drug at the site targeted by the ligand unit.

[0026] The activatable self-sacrificing part comprises an activatable group (AG) and a self-sacrificing spacer unit. Activation of the activatable group, for example by enzymatic conversion of an amide group to an amino group or by reduction of a disulfide to a free thiol group, initiates a self-sacrificing reaction sequence that leads to the release of the free drug through one or more mechanisms, which may involve the 1,6-elimination of a p-aminobenzyl group to a p-quinone methylate, optionally accompanied by the release of carbon dioxide and / or a subsequent second cyclization release mechanism. The self-sacrificing assembly unit may be part of a chemical spacer linking the antibody and the payload (via a functional group). Alternatively, the self-sacrificing group is not an inherent part of the chemical spacer but a branch from the chemical spacer linking the antibody and the payload.

[0027] "Cetase-cleavable peptide" is defined herein as a peptide subset in which the peptide bond can be cleaved via a proteolytic process mediated by one or more proteases selected from the cathepsin family of proteases, particularly cathepsin B and / or cathepsin D, more particularly cathepsin B.

[0028] "Plant protein cleavable peptide" is defined herein as a peptide fraction in which peptide bonds can be cleaved via a proteolytic process mediated by cysteine-containing pluton protein (asparagine endopeptidase).

[0029] A “conjugate” is defined herein as a compound in which an antibody is covalently linked to a payload via a linker. A conjugate comprises one or more antibodies and / or one or more payloads.

[0030] The term "payload" refers to a portion of a molecule covalently linked to a target moiety (such as an antibody) and also to a molecule released from the conjugate upon absorption of the protein conjugate and / or cleavage linker. Therefore, a payload refers to a monovalent moiety with an open end covalently linked to the target moiety via a linker, and also to the molecule released from it.

[0031] The term "hydrophobic drug" is defined in this paper as the clogP value (the calculated logarithm of its partition coefficient between n-octanol and water log(c octanol / c water For drugs with a cLogP value ≥ 3, the cLogP value can be estimated using CDD Vault software (Collaborative Drug Discovery Inc.) based on the method described in Gedeck et al., 2017, J. Chem. Inf. Model. 57, 8, 1847-1858. Model training information using publicly available datasets is available from CDD.

[0032] Aggregation is the process by which molecules self-associate with each other. In the context of this invention, the level of aggregation is assessed during the conjugation of the linker construct with the antibody. During conjugation, aggregation is quantified based on the percentage of monomer content. A high percentage of monomer values ​​generally equates to a lower degree of aggregation. A percentage of monomer values ​​of 93% or 95% or higher generally means that the level of aggregation is negligible or nonexistent, while values ​​below this threshold generally indicate a high level of aggregation.

[0033] describe

[0034] The inventors of this case have developed antibody-drug conjugates comprising an active ingredient and a novel polyglycine linker system, which exhibit a negligible tendency to aggregate, particularly since the active ingredient is a hydrophobic drug, and the polyglycine linker system imparts increased hydrophilicity to the ADC, thus resulting in a negligible tendency to aggregate. The resulting ADC has been found to exhibit significant in vivo efficacy. Furthermore, the resulting ADC has been found to exhibit improved conjugation efficiency.

[0035] This invention relates first and foremost to antibody-drug conjugates. In a second aspect, the invention relates to a method for synthesizing the antibody-drug conjugates of the invention. In a third aspect, the invention relates to a linker-drug construct suitable for use in the method according to the invention. In a fourth aspect, the invention relates to the medical use of the antibody-drug conjugates according to the invention, and pharmaceutical compositions comprising the antibody-drug conjugates according to the invention. Those skilled in the art will understand that all aspects are interconnected, and everything described for the antibody-drug conjugates according to the invention equally applies to the method according to the invention, the linker-drug construct according to the invention, the use according to the invention, and the composition according to the invention, and vice versa.

[0036] The present invention can be defined according to the following list of preferred embodiments: This invention provides an antibody-drug conjugate having structure (1). (1)

[0038] in: AB is a cell-binding agent, such as an antibody; n is an integer in the range of 5 to 8; L 1 For connectors; L 2 For connectors; L 3 For connectors; a, b, and c are independently 0 or 1; Z is a linker group obtained by metal-free click reaction, thiol bonding, or transglutaminase-mediated transamidation. Or Z is absent, where a and b are 0, and the N-terminus of polyglycine is directly bonded to AB in the absence of a sorting enzyme recognition sequence motif; D represents the effective drug load; x is an integer in the range of 1 to 8.

[0039] In one implementation, n is 5, 6, or 7. In another implementation, n is 5 or 6. In yet another implementation, n is 5.

[0040] In one embodiment, the present invention provides the antibody-drug conjugate of the present invention, wherein L 3 It contains cathepsin-cleavable peptides or pod protein-cleavable peptides, especially cathepsin-cleavable peptides.

[0041] In one embodiment, the present invention provides an antibody-drug conjugate of the present invention, wherein L 3 for , The antibody-drug conjugate has structure (1a).

[0042] (1a)

[0043] in: AB is a cell-binding agent, such as an antibody; n is an integer in the range of 5 to 8; L 1 For connectors; L 2 For connectors; L 3a For connectors; a, b, and d are independently 0 or 1; Z is a linker group obtained by metal-free click reaction, thiol bonding, or transglutaminase-mediated transamidation. Or Z is absent, where a and b are 0, and the N-terminus of polyglycine is directly conjugated to AB in the absence of a sorting enzyme recognition sequence motif; D represents the effective drug load; p is an integer in the range of 1 to 5; Each R 11 Independent of amino acid side chains; x is an integer in the range of 1 to 8.

[0044] In one embodiment, the present invention provides an antibody-drug conjugate of the present invention, wherein the peptide (NH-CR) 11 -CO)p is selected from Val-Cit, Glu-Val-Cit, Val-Ala, Val-Lys, Val-Arg, Aclys-Val-Cit, Aclys-Val-Ala, Glu-Val-Ala, Asp-Val-Ala, Phe-Gly, Phe-Cit, Phe-Ala, Phe-Lys, Phe-Arg, Ala-Lys, Leu-Cit, Ile-Cit, Trp-Cit, Ala-Ala-Asn, Ala-Asn, Asn-Asn, and Lys, especially from Val-Cit, Glu-Val-Cit, Val-Ala, Glu-Val-Ala, Val-Lys, Phe-Gly, Phe-Cit, Phe-Ala, Phe-Lys, Ala-Ala-Asn, and even more especially from Val-Cit or Val-Ala.

[0045] In one embodiment, p is 2 or 3, particularly 2. In another embodiment, p is 2 or 3, particularly 2, and n is 5.

[0046] In one embodiment, d is 0. In another embodiment, d is 0 and p is 2 or 3, particularly 2. In yet another embodiment, d is 0 and p is 2 or 3, particularly 2 and n is 5.

[0047] In one embodiment, the present invention provides an antibody-drug conjugate of the present invention, wherein L 3 It contains a self-sacrificing group. In another embodiment, L 3 It contains an activatable self-sacrificing group.

[0048] In another embodiment, the self-sacrificing group is a para-aminobenzyloxycarbonyl (PABC) derivative.

[0049] p-Aminobenzyloxycarbonyl (PABC) derivatives can be derived from the general formula (L 4 )express:

[0050] (L 4 )

[0051] in: A is an optionally substituted 5- or 6-membered aromatic ring or heteroaromatic ring; R 21 Selected from H, R 22 C(O)OH and C(O)R 22 , where R 22 For C1-C 24 (Hetero)alkyl, C3-C 10 (Hetero)cycloalkyl, C2-C 10 (Miscellaneous) aryl, C3-C 10 Alkyl (hetero)aryl and C3-C 10 (Hetero)arylalkyl, optionally composed of one or more elements selected from O, S, and NR. 23 The heteroatom is substituted and optionally interdoped with the heteroatom, wherein R 23 The group consisting of hydrogen and C1-C4 alkyl groups is selected independently.

[0052] In another embodiment, the self-sacrificing group is an activatable self-sacrificing part, and A is replaced by an activatable group (AG). In another embodiment, AG is selected from... , and

[0053] in

[0054] Each R 31 Independently selected from hydrogen and acetyl groups; and R 32 It is hydrogen or C1-C6 alkyl.

[0055] In one embodiment, A is an optionally substituted phenyl, particularly an optionally substituted 1,4-phenyl.

[0056] Specifically, the self-sacrificing group is an activatable self-sacrificing part, and A is a phenyl group substituted with an activatable group (AG). The p-aminobenzyloxycarbonyl (PABC) derivative can be derived from the general formula (L... 4a )express:

[0057] (L 4a )

[0058] Among them, AG and R 21 It can be described as anywhere in this article.

[0059] In one implementation, L3 comprises a self-sacrificing group, which is formed by the general formula (L 4 ) or (L 4a ) represents the p-aminobenzyloxycarbonyl (PABC) derivative.

[0060] In a particular implementation, L 3 It is a self-sacrificing group, which is composed of the general formula (L 4 ) or (L 4a ) represents the p-aminobenzyloxycarbonyl (PABC) derivative.

[0061] In one implementation, L3 a It is a self-sacrificing group, which is composed of the general formula (L 4 ) or (L 4a ) represents the p-aminobenzyloxycarbonyl (PABC) derivative.

[0062] In one embodiment, the present invention provides an antibody-drug conjugate of the present invention having structure (1b).

[0063] (1b)

[0064] in: AB is a cell-binding agent, such as an antibody; n is an integer in the range of 5 to 8; L 1 For connectors; L2 For connectors; a and b are independently 0 or 1; Z is a linker group obtained by metal-free click reaction, thiol bonding, or transglutaminase-mediated transamidation. Or Z is absent, where a and b are 0, and the N-terminus of polyglycine is directly bonded to AB in the absence of a sorting enzyme recognition sequence motif; D represents the effective drug load; p is an integer in the range of 0 to 5; Each R 11 Independent of amino acid side chains; A is an optionally substituted 5- or 6-membered aromatic ring or heteroaromatic ring; R 21 Selected from H, R 22 C(O)OH and C(O)R 22 , where R 22 For C1-C 24 (Hetero)alkyl, C3-C 10 (Hetero)cycloalkyl, C2-C 10 (Miscellaneous) aryl, C3-C 10 Alkyl (hetero)aryl and C3-C 10 (Hetero)arylalkyl, optionally composed of one or more elements selected from O, S, and NR. 23 The heteroatom is substituted and optionally interdoped with the heteroatom, wherein R 23 The group consisting of hydrogen and C1-C4 alkyl groups is selected independently.

[0065] x is an integer in the range of 1 to 8.

[0066] In one embodiment, where a=0 and the conjugation site is a cysteine ​​residue, particularly a cysteine ​​residue naturally present in the antibody, optionally after disulfide bond reduction, or wherein the cysteine ​​residue is engineered, particularly by replacing an amino acid with cysteine, inserting cysteine, or introducing a single cysteine ​​residue or a peptide fragment containing a cysteine ​​residue at the N or C terminus.

[0067] In an alternative embodiment, where a=0 and the conjugation site is a glutamine residue, particularly a glutamine residue naturally present in the antibody, or where the glutamine residue is engineered, preferably by replacing an amino acid with glutamine, inserting glutamine, or introducing a single glutamine residue or a peptide fragment containing a glutamine residue at the N or C terminus.

[0068] In one embodiment, the antibody-drug conjugate has structure (1c).

[0069] (1c)

[0070] Z, L 2 L 3 D, b, c, n, and x are as defined in this paper; e is an integer in the range of 0 to 20; Su is a monosaccharide; G is a monosaccharide fraction; GlcNAc is the N-acetylglucosamine moiety; Fuc is a fucose fraction; m is 0 or 1.

[0071] In one embodiment, the antibody-drug conjugate has a structure (1d).

[0072] (1d)

[0073] Z, L 2 L 3 D, b, c, n, and x are as defined in this paper; L 1 -NH-L 5 L 5 For connectors.

[0074] The antibody-drug conjugate according to any of the foregoing embodiments, wherein the drug loading is a hydrophobic drug.

[0075] According to any of the foregoing embodiments, the antibody-drug conjugate is camptothecin or a derivative thereof, such as ethatecan or a derivative thereof, such as ethatecan or deruxtecan, especially ethatecan.

[0076] Specifically, D is essanotecan, wherein the drug linker can be cleaved under cellular conditions to release a drug having the following formula (D 1 Isanotecan:

[0077] (D 1 )

[0078] In another aspect, the present invention provides a method for synthesizing the antibody-drug conjugate of the present invention, comprising making...

[0079] (i) has the structure AB-((L 1 ) a -F)x modified antibodies, where: AB represents antibodies; L1 For connectors; a is 0 or 1; F is a click probe that can react with Q in a metal-free click reaction, or a thiol or its precursor, or an acyl donor that can react with Q in transglutaminase-mediated transamidation. x is an integer in the range of 1 to 8; and (ii) Linker-drug construct based on structure (5): (5)

[0081] in: Q is a click probe capable of metal-free click reactions, or a thiol-reactive probe, or an acyl acceptor probe capable of reacting with acyl donor F in transglutaminase-mediated transamidation. L 2 L 3 D, n, b, and c are as defined in this paper; The reaction is carried out to form an antibody-drug conjugate, wherein the drug is covalently linked to the antibody via a linker group Z, which is formed by a metal-free click reaction between Q and F, or by thiol bonding between Q and F, or by transglutaminase-mediated transamidation between Q and F.

[0082] In one embodiment, the click probe Q comprises a cycloalkyne moiety, a cycloalkene moiety, or a tetrazine moiety; or the thiol reactive probe Q comprises a maleimide moiety.

[0083] In one implementation, the probe Q is selected from the group consisting of: optionally substituted heterocyclopropenyl, heterocyclobutenyl, trans-heptenyl, trans-octenyl, trans-nonenyl, or trans-decynyl.

[0084] In one embodiment, the acyl acceptor probe Q is selected from amines, such as primary amines; hydrazides; acyl hydrazides; alkoxyamines; or aryloxyamines. In another embodiment, the amine, hydrazine, acyl hydrazine, or hydroxylamine is an aryl derivative, particularly a optionally substituted phenyl derivative or an optionally substituted benzyl derivative, such as an optionally substituted phenylhydrazine. In one embodiment, the acyl acceptor is a hydrazine or an acyl hydrazine. In one embodiment, the acyl acceptor is an acyl hydrazine or an optionally substituted aryl hydrazine derivative. In yet another embodiment, the acyl acceptor is an optionally substituted phenylhydrazine or an optionally substituted phenylyl hydrazine derivative.

[0085] In one embodiment, the click probe F is selected from the group consisting of: azides, tetrazides, triazines, nitrones, nitriles, nitriles, nitrile imides, diazo compounds, ortho-quinones, dioxothiophenes, syl ketones, and cycloalkenes, with the click probe F preferably being an azide moiety.

[0086] In one embodiment, the method of the present invention wherein the click reaction is a 1,3-dipolar cycloaddition or a (4+2) cycloaddition.

[0087] In one implementation, F is a thiol.

[0088] In one embodiment, the thiol conjugation is a nucleophilic reaction, preferably Michael addition or nucleophilic substitution.

[0089] In one embodiment, where a=0 and the conjugation site is a cysteine ​​residue, particularly a cysteine ​​residue naturally present in the antibody, optionally after disulfide bond reduction, or wherein the cysteine ​​residue is engineered, preferably by replacing an amino acid with cysteine, inserting a cysteine ​​residue, or introducing a single cysteine ​​residue or a peptide fragment containing a cysteine ​​residue at the N or C terminus.

[0090] In one embodiment: the click probe F is selected from the group consisting of: azides, tetrazides, triazines, nitrones, nitriles, nitriles, nitrile imines, diazo compounds, ortho-quinones, dioxothiophenes, syl ketones, and cyclic olefin moieties, particularly the click probe F being an azide moiety; and / or wherein the click reaction is a 1,3-dipolar cycloaddition or a (4+2) cycloaddition; or F is a thiol; and / or wherein the thiol conjugation is a Michael addition or a nucleophilic substitution.

[0091] In an alternative embodiment, F is an acyl donor capable of reacting with the acyl acceptor probe Q in transglutaminase-mediated transamidation. F is an acyl derivative, particularly an amide or carboxylic acid derivative, and specifically, the acyl group is located in the side chain of an amino acid residue. Specifically, the amino acid is glutamine. Specifically, a is 0, and the amino acid, particularly glutamine, is located in antibody AB.

[0092] In one embodiment, where a=0 and the conjugation site is a glutamine residue, particularly a glutamine residue naturally present in the antibody, or where the glutamine residue is engineered, preferably by replacing an amino acid with glutamine, inserting glutamine, or introducing a single glutamine residue or a peptide fragment containing a glutamine residue at the N or C terminus.

[0093] In one embodiment of the method of the present invention, AB-((L 1 )aF)x is based on structure (6): (6)

[0095] Where F and x are defined in this paper as follows: e is an integer in the range of 0 to 10; Su is a monosaccharide; G is a monosaccharide fraction; GlcNAc is the N-acetylglucosamine moiety; Fuc is a fucose fraction; m is 0 or 1.

[0096] In one embodiment of the method of the present invention, AB-((L 1 )aF)x is based on structure (7): (7)

[0098] Where F and x are defined as in this paper: L 1 -NH-L 5 .

[0099] In one implementation, L 1 -NH-NH-L 5 ', especially, L 1 -NH-NH-C(O)-L 5 ".

[0100] In one implementation, L 1 -NH-L 5 Furthermore, F is a click probe capable of performing metal-free click reactions.

[0101] In one implementation, -NH-L 5 The terminal NH group of the antibody is conjugated to glutamine residues in the antibody.

[0102] In one embodiment, the method of the present invention further includes the step of: passing H2N-L 5 -F and antibodies are combined via transglutaminase-mediated transamidation to prepare antibody-linker constructs with structure 7.

[0103] On the other hand, the present invention provides a linker-drug construct according to structure (5): (5)

[0105] in: Q is a click probe capable of metal-free click reactions, or a thiol-reactive probe, or an acyl acceptor probe capable of reacting with acyl donor F in transglutaminase-mediated transamidation. L2 L 3 D, n, b, and c are as defined in this paper.

[0106] In one embodiment, the click probe Q comprises a cycloalkyne moiety or a cycloalkene moiety, or wherein the thiol reactive probe Q comprises a maleimide moiety.

[0107] In one embodiment, the click probe Q comprises a cycloalkyne moiety or a cycloolefin moiety.

[0108] In one implementation, the click probe Q contains a tetrazine portion.

[0109] In one implementation, the probe Q is selected from the group consisting of: optionally substituted heterocyclopropenyl, heterocyclobutenyl, trans-heptenyl, trans-octenyl, trans-nonenyl, or trans-decynyl.

[0110] In another aspect, the present invention provides a pharmaceutical composition comprising the antibody-drug conjugate of the present invention and a pharmaceutically acceptable carrier.

[0111] In another aspect, the present invention provides antibody-drug conjugates for use in treating subjects in need.

[0112] In another aspect, the present invention provides antibody-drug conjugates for the treatment of cancer.

[0113] In another aspect, the present invention provides an antibody-drug conjugate for use according to the invention, wherein the cancer is HER2-positive cancer, preferably breast cancer, gastric cancer, colon cancer, lung cancer, pancreatic cancer, urothelial carcinoma, brain cancer, or ovarian cancer.

[0114] Antibody-drug conjugates

[0115] The antibody-drug conjugate according to the present invention has a structure (1): (1)

[0117] in: AB is a cell-binding agent, such as an antibody; n is an integer in the range of 5 to 8; L 1 For connectors; L 2 For connectors; L 3 For connectors; a, b, and c are independently 0 or 1; Z is a linker group obtained by metal-free click reaction, thiol bonding, or transglutaminase-mediated transamidation. Or Z is absent, where a and b are 0, and the N-terminus of polyglycine is directly bonded to AB in the absence of a sorting enzyme recognition sequence motif; D represents the effective drug load; x is an integer in the range of 1 to 8.

[0118] The conjugates according to the invention comprise polyglycine (Gly)n linkers, wherein n is an integer in the range of 5 to 8. The conjugates according to the invention may comprise self-sacrificing groups and / or cleavable linkers, particularly peptide spacers and / or p-aminobenzyloxycarbonyl (PABC) moieties or derivatives thereof.

[0119] Specifically, n is 5, 6, or 7; more specifically, n is 5 or 6; and most specifically, n is 5.

[0120] In particular, the antibody-drug conjugate of the present invention comprises a cathepsin-cleavable peptide.

[0121] Peptide spacers are composed of (NH-CR) 11 -CO)p is defined, where R 11 This indicates an amino acid side chain as known in the art. In this document, amino acids can be natural or synthetic. Specifically, all amino acids are in their L-configuration. p is an integer in the range of 1 to 5, particularly an integer in the range of 2 to 5. Therefore, the peptide spacer contains 1 to 5 amino acids. Specifically, the peptide is a dipeptide (p=2) or a tripeptide (p=3), and most preferably, the peptide spacer is a dipeptide. Although any peptide spacer can be used, in particular, the peptide spacer is selected from Val-Cit, Glu-Val-Cit, Val-Ala, Val-Lys, Val-Arg, AcLys-Val-Cit, AcLys-Val-Ala, Glu-Val-Ala, Asp-Val-Ala, Phe-Gly, Phe-Cit, Phe-Ala, Phe-Lys, Phe-Arg, Ala-Lys, Leu-Cit, Ile-Cit, Trp-Cit, Ala-Ala-Asn, Asn-Asn, Ala-Asn, and Lys, preferably selected from Val-Cit, Glu-Val-Cit, Val-Ala, Glu-Val-Ala, Val-Lys, and Phe-Gly. Phe-Cit, Phe-Ala, Phe-Lys, and Ala-Ala-Asn are most preferably selected from Val-Cit or Val-Ala. In one embodiment, the peptide spacer is Val-Cit. In another embodiment, the peptide spacer is Val-Ala.

[0122] In one implementation, the peptide spacer and the polyglycine linker (Gly) n Adjacent to each other, forming an uninterrupted polypeptide. In one embodiment, such an uninterrupted polypeptide contains the peptide sequence Gly-Gly-Phe-Gly (GGFG) at its C or N terminus.

[0123] In one implementation, L 3 Having structure L 3'

[0124] (L 3' )

[0125] in

[0126] R 11 Indicates the side chain of an amino acid; L 3a For connectors; d is 0 or 1; p is an integer in the range of 1 to 5.

[0127] In particular, R 11 The side chains are selected from alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, acetyllysine, leucine, methionine, asparagine, pyrrolidone, proline, glutamine, arginine, serine, threonine, selenocysteine, valine, tryptophan, tyrosine, and citrulline. Specific amino acid side chains are those of Val, Cit, Ala, Lys, Arg, AcLys, Phe, Leu, Ile, Trp, Glu, Asp, and Asn, more preferably from the side chains of Val, Cit, Ala, Glu, and Lys. In other words, R 11 Preferably selected from CH3 (Ala), CH2CH(CH3)2 (Leu), CH2CH2CH2NHC(O)NH2 (Cit), CH2CH2CH2CH2NH2 (Lys), CH2CH2CH2NHC(O)CH3 (AcLys), CH2CH2CH2NHC(=NH)NH2 (Arg), CH2Ph ​​(Phe), CH(CH3)2 (Val), CH(CH3)CH2CH3 (Ile), CH2C(O)NH2 (Asn), CH2CH2C(O)OH (Glu), CH2C(O)OH (Asp), and CH2(1H-indole-3-yl)(Trp). 11The most specific embodiments are CH3 (Ala), CH2CH2CH2NHC(O)NH2 (Cit), CH2CH2CH2CH2NH2 (Lys), CH2CH2C(O)OH (Glu), and CH(CH3)2 (Val). Most particularly, R 11 It can be CH3 (Ala), CH2CH2CH2NHC(O)NH2 (Cit), CH2CH2CH2CH2NH2 (Lys) or CH(CH3)2 (Val).

[0128] In particular, peptide spacers can be constructed using the general formula (L... 3b )express:

[0129] (L 3b )

[0130] Among them, R 11 As defined above, in particular, R11 is CH3 (Ala) or CH2CH2CH2NHC(O)NH2 (Cit).

[0131] The wavy line indicates the connection to the rest of the conjugate.

[0132] Specifically, p is 2, and even more specifically, p is 2 and n is 5.

[0133] In one embodiment, the present invention provides an antibody-drug conjugate of the present invention having structure (1a).

[0134] (1a)

[0135] in: AB is a cell-binding agent, such as an antibody; n is an integer in the range of 5 to 8; L 1 For connectors; L 2 For connectors; L 3a For connectors; a, b, and d are independently 0 or 1; Z is a linker group obtained by metal-free click reaction, thiol bonding, or transglutaminase-mediated transamidation. Or Z is absent, where a and b are 0, and the N-terminus of polyglycine is directly conjugated to AB in the absence of a sorting enzyme recognition sequence motif; D represents the effective drug load; p is an integer in the range of 1 to 5; Each R 11 Independent of amino acid side chains; x is an integer in the range of 1 to 8.

[0136] The antibody-drug conjugate of the present invention, wherein L 3 It may contain self-sacrificing groups, especially activatable self-sacrificing groups.

[0137] In particular, the self-sacrificing group is a para-aminobenzyloxycarbonyl (PABC) derivative.

[0138] p-Aminobenzyloxycarbonyl (PABC) derivatives can be derived from the general formula (L 4 )express:

[0139] (L 4 )

[0140] in; A is an optionally substituted 5- or 6-membered aromatic ring or heteroaromatic ring; R 21 Selected from H, R 22 C(O)OH and C(O)R 22 , where R 22 For C1-C 24 (Hetero)alkyl, C3-C 10 (Hetero)cycloalkyl, C2-C 10 (Miscellaneous) aryl, C3-C 10 Alkyl (hetero)aryl and C3-C 10 (Hetero)arylalkyl, optionally composed of one or more elements selected from O, S, and NR. 23 The heteroatom is substituted and optionally interdoped with the heteroatom, wherein R 23 The group consisting of hydrogen and C1-C4 alkyl groups is selected independently.

[0141] The wavy line indicates the connection to the rest of the conjugate.

[0142] Suitable 5-membered rings are oxazoles, thiazoles, and furans. Suitable 6-membered rings are phenyl and pyridyl. In particular, A is optionally substituted with 1,4-phenyl, 2,5-pyridyl, or 3,6-pyridyl. Most particularly, A is 1,4-phenyl.

[0143] Specifically, the self-sacrificing group is an activatable self-sacrificing moiety, and A is replaced by an activatable group (AG). More specifically, AG is selected from... , and

[0144] in

[0145] Each R 31 Independently selected from hydrogen and acetyl groups; and R 32 It is hydrogen or C1-C6 alkyl.

[0146] The wavy line indicates the connection with A.

[0147] In particular, R 31 and R 32 It is hydrogen.

[0148] Specifically, the self-sacrificing group is an activatable self-sacrificing part, and A is a phenyl group substituted with an activatable group (AG). The p-aminobenzyloxycarbonyl (PABC) derivative can be derived from the general formula (L... 4a )express:

[0149] (L 4a )

[0150] Among them, AG and R 21 It can be described as anywhere in this article.

[0151] In particular, the antibody-drug conjugate of the present invention has structure (1b).

[0152] (1b)

[0153] in: AB represents antibodies; n is an integer in the range of 5 to 8; L 1 For connectors; L 2 For connectors; L 3a For connectors; a and b are independently 0 or 1; Z is a linker group obtained by metal-free click reaction, thiol bonding, or transglutaminase-mediated transamidation. Or Z is absent, where a and b are 0, and the N-terminus of polyglycine is directly bonded to AB in the absence of a sorting enzyme recognition sequence motif; D represents the effective drug load; p is an integer in the range of 0 to 5; Each R 11 Independent of amino acid side chains; A is an optionally substituted 5- or 6-membered aromatic ring or heteroaromatic ring; R 21 Selected from H, R 22C(O)OH and C(O)R 22 , where R 22 For C1-C 24 (Hetero)alkyl, C3-C 10 (Hetero)cycloalkyl, C2-C 10 (Miscellaneous) aryl, C3-C 10 Alkyl (hetero)aryl and C3-C 10 (Hetero)arylalkyl, optionally composed of one or more elements selected from O, S, and NR. 23 The heteroatom is substituted and optionally interdoped with the heteroatom, wherein R 23 Independently selected from the group consisting of hydrogen and C1-C4 alkyl groups, x is an integer in the range of 1 to 8.

[0154] Suitable 5-membered rings are oxazoles, thiazoles, and furans. Suitable 6-membered rings are phenyl and pyridyl. In particular, A is optionally substituted with 1,4-phenyl, 2,5-pyridyl, or 3,6-pyridyl. Most particularly, A is 1,4-phenyl. In particular, where the phenyl group is replaced by an activatable group AG, A is as described above in the general formula (L 4a ) represents 1,3,4-phenyl as defined in the context of the p-aminobenzyloxycarbonyl (PABC) derivative.

[0155] In particular, R 21 For H or C(O)R 22 , where R 22 =4-methylpiperazine or morpholine. Specifically, R 21 For H.

[0156] Connector (L) 1 、L 2 、L 3 and L 3a )

[0157] Connectors (also known as "connection units") are well known in the art, and any suitable connector can be used. In the context of this invention, the payload is transmitted via connector L. 3 Chemically linked to a polyglycine linker (Gly). n Polyglycine linker (Gly) n via connector L 2 The linker group Z is chemically attached to a linker group L, wherein the linker group Z is obtained by a metal-free click reaction, thiol bonding, or transglutaminase-mediated transamidation, and the linker group Z is connected via a linker L. 1Chemically linked to the antibody. Linkers, especially linkers L... 2 It may contain one or more branch points for connecting multiple payloads to a single linker group.

[0158] Connector L 1 It may exist (a=1) or not exist (a=0). In connector L 1 If it does not exist, click probe F to connect directly to the antibody.

[0159] Typically, when the conjugation occurs via thiol bonding, a = 0. Typically, when the conjugation occurs via a click reaction, a = 1.

[0160] In the absence of Z, with a=0 and b=0, the polyglycine linker (Gly) n In the absence of a sorting enzyme recognition sequence motif, the N-terminus of the antibody can bind directly to the antibody via transglutaminase, particularly microbial transglutaminase (MTGase).

[0161] Connectors can be selected from, for example, groups consisting of straight chains or branches C1-C. 200 Alkylene, C2-C 200 alkenyl, C2-C 200 Ethyne group, C3-C 200 Cycloalkylene, C5-C 200 Cycloalkylene, C8-C 200 cycloacetylenic, C7-C 200 Alkyl arylene, C7-C 200 Arylalkylene, C8-C 200 Aryleneide group, C9-C 200 Arylynylene. Optionally, alkylene, alkenylene, ynylene, cycloalkylene, cycloalkenylene, cycloalkynylene, alkylarylene, arylalkylene, arylalkenylene, and arylynylene can be substituted, and optionally, the group may be intercalated with one or more heteroatoms, preferably 1 to 100 heteroatoms, wherein the heteroatoms are preferably selected from O, S(O)y, and NR. 12 The group consists of y, where y is 0, 1, or 2, preferably y=2, and R 12 Independently select from the following groups: hydrogen, halogens, C1-C 24 Alkyl, C8-C 24 (Miscellaneous)aryl, C1-C 24 Alkyl (hetero)aryl and C1-C 24 (Hetero)arylalkyl.

[0162] In particular, L 2 It does not contain (poly)glycol linkers. Specifically, L 3If present, it does not contain polyethylene glycol linkers. Specifically, L 2 and L 3 If present, then none of them contain polyethylene glycol linkers.

[0163] In particular, L 2 Selected from -(CR) 1 R 2 )y-、-(CR 1 R 2 )yC(O)- and -C(O)-(CR 1 R 2 )yC(O)-, where y is an integer in the range of 0 to 6, wherein one or more CR1R 2 Can be arbitrarily NR 1 Substitution; R 1 and R 2 Independently selected from H and R 2a C(O)OH and C(O)R 2a , where R 2a Selected from optionally substituted C1-C6 (hetero)alkyl, C3-C 10 (Hetero)cycloalkyl, C6-C 10 (Miscellaneous) aryl, C7-C 14 Alkyl (hetero)aryl and C7-C 14 (Hetero)arylalkyl.

[0164] In particular, R 1 and R 2 For H.

[0165] In one implementation, L 2 -(CH2) 1-5 -C(O)-. In a particular implementation, L 2 It is -CH2C(O)- or -CH2CH2C(O)-.

[0166] In one implementation, L 2 It is -C(O)-(CH2) 1-5 -C(O)-. In a particular implementation, L 2 It is -C(O)(CH2)2C(O)- or -C(O)(CH2)4C(O)-.

[0167] Branch body

[0168] In one embodiment, the linker of the conjugate according to the invention contains a branched portion. In the context of this invention, a "branched portion" refers to a portion embedded in a linker connecting three portions. In other words, the branched portion contains at least three bonds connecting to the other portions, typically one bond connecting to antibody AB, one bond connecting to Z, one bond connecting to the payload, and one bond connecting to a second payload. The branched portion is preferably embedded in linker L. 2 In the context of this invention, any part containing at least three bonds connected to other parts is suitable as a branched part. In a preferred embodiment, the branched part BM is selected from carbon atoms, nitrogen atoms, phosphorus atoms, (hetero)aromatic rings, (hetero)cyclic rings, or polycyclic parts. Most preferably, the branched part is a nitrogen atom.

[0169] In one implementation, connector L 2 It contains branched parts, particularly via nitrogen atoms, which enable two payloads to be connected to a single part Z.

[0170] In a particular implementation, L 2 It has structure (2): (2)

[0172] Among them, using The marked tilde is connected to Z, and is used with The marked tilde is linked to the N-terminal NH group of the polyglycine linker. LB 1 and LB 2 Each is a separate linker component, and the two linker-load components connected to the branched nitrogen atom may be the same or different. Specifically, D is the same every time it appears. In a particular embodiment, LB... 2 It is the same every time it appears. In a particular implementation, n is the same every time it appears. Specifically, L 3 c is the same every time it appears.

[0173] Linking group Z

[0174] Z is a linker group. The term "linker group" refers to a structural element that links one part of a conjugate to another part of the same biological conjugate. In (1), Z links antibody AB to the payload via a linker. The linker group Z is a partial form that can be obtained by metal-free click reaction, by thiol conjugation, or by transglutaminase-mediated transamidation. As will be understood by those skilled in the art, the exact properties of Z depend on the properties of F and Q. Preferred embodiments of Q and F are further defined below.

[0175] In the first embodiment, the linking group Z can be obtained by a metal-free click reaction. Hereinafter, the linking group Z may contain a triazole moiety, an isoxazole moiety, a dihydroisoxazole moiety, a bicyclic [2.2.2]oct-5,7-diene-2,3-dione moiety, a bicyclic [2.2.2]oct-5-ene-2,3-dione moiety, a 7-thiabicyclic [2.2.1]hept-2,5-diene-7,7-dioxide moiety, a 7-thiabicyclic [2.2.1]hept-2-ene-7,7-dioxide moiety, a pyrazole moiety, a pyridine moiety, a dihydropyridine moiety, a pyridazine moiety, or a dihydropyridazine moiety.

[0176] In a particular embodiment, Q contains a cycloalkyne moiety and F is an azide, and Z contains a triazole moiety formed by 1,3-dipolar cycloaddition of the alkyne moiety and the azide moiety.

[0177] In a second specific embodiment, the linking group Z can be obtained by thiol bonding, wherein the linking group Z has a group that is bonded to L. 2 The connection and at least one connection to AB may be via L 1 A linking group Z can also have two links to AB, where a cross-linked thiol reactive probe Q is used. In one embodiment, L 1 There is no (a=0) and Z is directly linked to AB. In a particular embodiment, the linking group Z comprises a succinimide ring or an open-ring succinic acid amide derivative thereof.

[0178] In a third specific embodiment, the linker group Z can be obtained by transglutaminase-mediated transamidation, wherein the linker group Z has a group that is related to L. 2 The connection and at least one connection to AB may be via L 1 In one implementation, L 1 There is no (a=0) and Z is directly connected to AB.

[0179] Adhesion pattern

[0180] The conjugates according to the invention can be prepared by conjugation modes, wherein the conjugation reaction is thiol conjugation, or a metal-free click reaction, or transglutaminase conjugation, particularly microbial transglutaminase (MTGase). In the absence of Z, with a=0 and b=0, the N-terminus of the polyglycine linker (Gly)n is directly conjugated to the antibody, for example via transglutaminase conjugation, particularly microbial transglutaminase (MTGase).

[0181] Modified antibody AB-((L) 1 Properties of )aF)x, especially L 1The properties of a and x depend on the conjugation pattern used. x refers to the number of (L1)a linkage sites (conjugation sites) on the antibody and is an integer ranging from 1 to 8. In the case where Z (in the conjugate) or F (in the modified antibody) is directly linked to the antibody, L... 1 It does not exist and a=0. In this implementation, the modified antibody can also be called AB-(F)x.

[0182] x indicates that it is optional via connector L 1 The amount of probe F present on the antibody is an integer ranging from 1 to 8. Specifically, x is an integer ranging from 1 to 6, more specifically x = 1, 2, 3, or 4, even more specifically x = 1 or 2, and most specifically x = 2. Generally, x refers to the average number of antibody-linked partial bodies Z. In certain embodiments, particularly where conjugation is performed via a click reaction, the conjugates according to the invention typically have the same amount of antibody-linked partial bodies Z, although the conjugation reaction may sometimes be slightly incomplete. It is noteworthy that each linker L... 2 It can contain more than one payload, such as each connector L 2 There are 1 or 2 effective load molecules.

[0183] In a particular embodiment, a=1 and the conjugation pattern involves the glycan of the antibody, preferably conjugated via an N-glycosylation site. Typically, the modified antibody comprises one or more glycans having the structure -GlcNAc(Fuc)m-(G)e-Su-F, where e is an integer in the range of 0 to 20; Su is a monosaccharide; G is a monosaccharide moiety; GlcNAc is an N-acetylglucosamine moiety; Fuc is a fucose moiety; and m is 0 or 1. In other words, L1 is specifically represented by -GlcNAc(Fuc)m-(G)e-Su-, where GlcNAc(Fuc)m is linked to the peptide portion of the antibody, and Su is linked to Z or F, GlcNAc being the core N-acetylglucosamine moiety, which is typically present in the glycan structure of the antibody. The core N-acetylglucosamine moiety refers to the N-acetylglucosamine moiety directly linked to the peptide chain of the antibody. This core N-acetylglucosamine moiety is optionally fucosylated (m is 0 or 1), which is a common feature of antibodies.

[0184] (G)e represents the glycoform of the antibody. This invention can be applied to antibodies of any glycoform. Typical monosaccharides present in glycans and from which G can be selected include glucose, galactose, mannose, fucose, N-acetylglucosamine, N-acetylgalactosamine, N-acetylneuraminic acid, and xylose. (G)e can therefore be a linear or branched oligosaccharide containing e monosaccharide moieties. Typical glycans have e in the range of 4 to 16, preferably 6 to 10. In a preferred embodiment, the antibody is modified and e = 0. This modification can be performed by an endoglucosidase (such as EndoS). The conjugation via the glycan preferably employs an N-glycosylation site, more preferably an N-glycosylation site linked to an asparagine amino acid of the antibody, and most preferably an N-glycosylation site linked to a conserved glycosylation site at amino acid N297 of the antibody.

[0185] Su is a monosaccharide containing F. Su is preferably selected from the group consisting of: galactose (Gal), mannose (Man), glucose (Glc), N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), N-acetylneuraminic acid or sialic acid (Sial), and fucose (Fuc). Su is preferably glucose or a galactose derivative, more preferably a galactose derivative, and most preferably N-acetylgalactosamine.

[0186] In an alternative embodiment, a=0 and the conjugation site at the antibody is a cysteine ​​residue, particularly wherein the cysteine ​​residue is naturally present in the antibody, optionally after reduction of a disulfide bond known in the art, or wherein the cysteine ​​residue is engineered, preferably by replacing an amino acid with cysteine, inserting cysteine, or introducing a single cysteine ​​residue or a peptide fragment containing a cysteine ​​residue at the N or C terminus.

[0187] In an alternative embodiment, a=0 and the conjugation site at the antibody is a glutamine residue, particularly wherein the glutamine residue is naturally present in the antibody, or wherein the glutamine residue is engineered, preferably by replacing an amino acid with glutamine, inserting glutamine, or introducing a single glutamine residue or a peptide fragment containing a glutamine residue at the N or C terminus.

[0188] In an alternative embodiment where Z is absent, a=0, and b=0, the N-terminus of the polyglycine linker (Gly)n is directly bonded to the antibody; in this embodiment, if Z is absent, then L 1 and L 2 Therefore, it does not exist. If Z does not exist, the N-terminus of the polyglycine linker (Gly)n will therefore directly bind to the antibody in the absence of any linker, for example, in the absence of any linker containing the sorting enzyme recognition sequence motif LPTXG (where X is any amino acid).

[0189] In one implementation, Z is absent, a=0, b=0, and the N-terminus of the polyglycine linker (Gly)n is directly conjugated to the antibody via transglutaminase, particularly microbial transglutaminase (MTGase).

[0190] Transglutaminases (TGases), particularly microbial transglutaminases (MTGases), catalyze the transamidation reaction between certain surface-exposed glutamine (Gln) residues and lysine (Lys) residues on a protein substrate, thereby cross-linking the glutamine and lysine residues via heteropeptide bonds. Examples of TGases include naturally occurring transglutaminases, mutant transglutaminases, engineered transglutaminases, recombinant transglutaminases, microbially derived transglutaminases, mammalian transglutaminases, and protein glutamine-γ-glutamyltransferases (EC 2.3.2.13), especially microbial transglutaminases (MTGases). The catalytic mechanism of MTGases involves nucleophilic attack on the target acyl donor Gln via the cysteine ​​residue at the enzyme's active site to form a thioester intermediate. The subsequent nucleophilic attack of the thioester by the amine substrate, acting as an acyl acceptor, leads to the formation of the transamidated product. Specifically, the conjugation site is Q295.

[0191] The most commonly used mTGase is a 38-kDa enzyme derived from *Streptomyces mobaraensis*. Another transglutaminase found in bacteria comes from *Bacillus subtilisin* (see US 5,731,183). Various variants of mTGase have been developed, such as those disclosed in WO2017 / 059158 and WO2017 / 059160 (Merck), which have amino acid substitutions selected from, for example, the group consisting of: (A) E300A, (B) I240A and P241A, (C) E249Q, and (D) E300A and Y302A.

[0192] AB represents antibody. Those skilled in the art will understand that this invention can be applied to any antibody.

[0193] Methods for synthesizing antibody-drug conjugates

[0194] In a second aspect, the present invention relates to a method for preparing an antibody-drug conjugate according to the invention. The method according to the invention comprises reacting (i) a modified antibody having the structure AB-((L1)aF)x with (ii) a linker-drug construct according to structure (5). The reaction is a conjugation reaction, which forms a covalent link between the payload and the antibody. The reaction is a metal-free click reaction, or thiol conjugation, or transglutaminase-mediated, particularly microbial transglutaminase-mediated, transamidation, and forms an antibody-drug conjugate, wherein the drug is covalently linked to the antibody via a linker group Z, which is formed by a metal-free click reaction between Q and F, or thiol conjugation between Q and F, or transglutaminase-mediated, particularly microbial transglutaminase-mediated, transamidation between Q and F. Alternatively, in the case where a=0 and b=0 and F is absent, the N-terminus of the polyglycine linker (Gly)n can be directly conjugated to the antibody, for example, via microbial transglutaminase (MTGase). In the method according to the invention, a modified antibody has the structure AB-((L1)aF)x, wherein AB is an antibody, L1 is a linker, a is 0 or 1, F is a click probe capable of reacting with Q in a metal-free click reaction, or a thiol or precursor capable of reacting with Q in a thiol conjugation, or an acyl donor capable of reacting with Q in a microbial transglutaminase-mediated transamidation, and x is an integer in the range of 1 to 8. A linker group Z is formed after F is reacted with Q of the linker-drug construct according to structure (5) via a metal-free click reaction, thiol conjugation, or transglutaminase-mediated transamidation. In one embodiment, the modified antibody may be referred to as AB-(F)x. Methods for preparing the modified antibody are known in the art, for example from WO2014 / 065661, WO2016 / 170186 and WO2016 / 053107, which are incorporated herein by reference. According to the same literature, the conjugation reaction between modified glycoproteins and linker-drug constructs containing cytotoxins and click probes is known to those skilled in the art.

[0195] In the method according to the invention, the linker-drug construct has a structure (5): (5)

[0197] in: Q is a click probe capable of metal-free click reactions, or a thiol-reactive probe, or an acyl acceptor probe capable of reacting with acyl donor F in transglutaminase-mediated transamidation. L 2 L 3 D, n, b, and c are defined as above.

[0198] Metal-free click reaction

[0199] Metal-free click reactions are well known in the art (see, for example, WO2014 / 065661 and Nguyen and Prescher, Nature rev. 2020, Digital Object Identifier: 10.1038 / s41570-020-0205-0, both incorporated herein by reference) and can typically take the form of 1,3-dipolar cycloaddition or (4+2) cycloaddition. Alkyne-azide cycloaddition can be strain-promoted (e.g., strain-promoted alkyne-azide cycloaddition, SPAAC). In certain embodiments, the bioconjugation reaction is a metal-free strain-promoted cycloaddition, most particularly a metal-free strain-promoted alkyne-azide cycloaddition. In certain embodiments, the conjugation is accomplished via cycloaddition, such as (4+2) cycloaddition or 1,3-dipolar cycloaddition, preferably 1,3-dipolar cycloaddition. A typical (4+2) cycloaddition is a Diels-Alder reaction, where Q is a diene or dienophile. As those skilled in the art will understand, the term "diene" in the case of a Diels-Alder reaction refers to a 1,3-(hetero)diene and includes conjugated dienes (R₂C=CR-CR=CR₂), imines (e.g., R₂C=CR-N=CR₂ or R₂C=CR-CR=NR, R₂C=NN=CR₂), and carboxyl groups (e.g., R₂C=CR-CR=O or O=CR-CR=O). Hetero-Diels-Alder reactions with dienes containing N and O are known in the art. Any diene known in the art suitable for (4+2) cycloaddition can be used as the reactive group Q. Specific dienes include tetrazines, 1,2-quinones, and triazines. Although any dienophile known in the art suitable for (4+2) cycloaddition can be used as the reactive group Q, the dienophile is particularly an alkenyl or alkynyl group as described above, and most particularly an alkynyl or cycloalkenyl group. For conjugations via (4+2) cycloaddition, Q can be a dienophile (and F is a diene), and more particularly, Q is or contains an alkynyl or cycloalkenyl group. Alternatively, for conjugations via (4+2) cycloaddition, Q can be a diene (and F is a dienophile), and more particularly, Q is or contains a tetrazinyl group.

[0200] For 1,3-dipolar cycloaddition, Q is a 1,3-dipolar or dipolarophile. Any 1,3-dipolar known in the art suitable for 1,3-dipolar cycloaddition can be used as the reactive group Q. Specific 1,3-dipolars include azide, nitroketone, oxynitrile, nitrileimine, and diazo groups. Although any dipolarophile known in the art suitable for 1,3-dipolar cycloaddition can be used as the reactive group Q, the dipolarophile is particularly alkenyl or ynyl, most particularly ynyl. For conjugations via 1,3-dipolar cycloaddition, in particular, Q is a dipolarophile (and F is a 1,3-dipolar), and more particularly, Q is or contains an ynyl group.

[0201] Therefore, in a particular embodiment, Q is selected from dipoleophiles and dienophiles.

[0202] Click probe Q

[0203] Click probe Q is used in conjugation reactions to link a linker-drug construct to an antibody having the structure AB-((L1)aF)x. Q is reactive to click probe F in metal-free click reactions. Such click probes are known in the art and include cyclic alkenes, cyclic alkynes, azides, tetrazides, triazines, nitrones, nitriles, nitriles, nitrile oxides, nitrile imines, diazo compounds, o-quinones, dioxothiophenes, and syldiones. In particular, Q is a cyclic alkene or cyclic alkyne moiety, and most particularly, Q is a cyclic alkyne moiety.

[0204] In a particular embodiment, the click probe Q comprises a cycloalkyne moiety. The alkynyl group may also be referred to as a (hetero)cycloalkyne, i.e., heterocyclic alkynyl or cycloalkyne, wherein the (hetero)cycloalkyne is optionally substituted. Specifically, the (hetero)cycloalkyne is (hetero)cycloheptyne, (hetero)cyclooctyne, (hetero)cyclopentyne, or (hetero)cyclodecyne. In this document, the (hetero)cycloalkyne may be optionally substituted. Specifically, the (hetero)cycloalkyne is optionally substituted (hetero)cycloheptyne or optionally substituted (hetero)cyclooctyne. Most particularly, the (hetero)cycloalkyne is (hetero)cyclooctyne, wherein the (hetero)cyclooctyne is optionally substituted.

[0205] Specific cycloalkynyl groups include optionally substituted bicyclic [6.1.0]non-4-yn-9-yl] (BCN group) or optionally substituted 2-azatricyclic [10.4.0.04,9]hexadecane-1(16),4,6,8,12,14-hexaden-10-yn-2-yl] (DBCO group).

[0206] Thiol conjugation

[0207] Thiol conjugation for the preparation of antibody-drug conjugates is well known in the art and can also be referred to as alkylation of thiol groups. It typically takes the form of a nucleophilic reaction, such as nucleophilic substitution or a Michael reaction. A specific Michael reaction is the maleimide-thiol reaction, which is widely used in bioconjugations. Therefore, in a particular embodiment, Q is reactive in a nucleophilic reaction, preferably in a nucleophilic substitution or a Michael reaction. Preferably, Q comprises a maleimide moiety, a haloacetamide moiety, an enamide moiety, an aminophosphonate moiety, a cyanoacetylene moiety, a vinyl sulfone, a vinylpyridine moiety, or a methanesulfonylphenyloxadiazole moiety, most preferably a maleimide moiety.

[0208] Thiol reactive probe Q

[0209] Thiol reactive probe Q is used in conjugation reactions to link linker-drug constructs to structures with AB-((L) 1 The antibody Q is reactive to thiols or their precursor F in thiol conjugation. Such probes are known in the art and can be selected from the group consisting of: maleimide moieties, haloacetamide moieties, enamide moieties, aminophosphonates, cyanoacetylene moieties, vinyl sulfones, vinylpyridine moieties, or methanesulfonylphenyloxadiazole moieties. Most particularly, Q comprises or is a maleimide moiety.

[0210] Transamidation mediated by transglutaminase (TGase)

[0211] Transglutaminases (TGases), particularly microbial transglutaminases (MTGases), catalyze the transamidation reaction between certain surface-exposed glutamine (Gln) residues and lysine (Lys) residues on protein substrates, thereby cross-linking the glutamine and lysine residues via isopeptide bonds. The catalytic mechanism of MTGases involves nucleophilic attack on the target acyl donor Gln via the enzyme's active site (cysteine) to form a thioester intermediate. Subsequently, the amine substrate, acting as an acyl acceptor, nucleophilically attacks the thioester, leading to the formation of the transamidated product. Specifically, the conjugation site is Q295.

[0212] The most commonly used mTGase is a 38-kDa enzyme derived from *Streptomyces mobara*. Another transglutaminase found in bacteria comes from *Bacillus subtilis* (see US 5,731,183). Various variants of mTGase have been developed, such as those disclosed in WO2017 / 059158 and WO2017 / 059160 (Merck), which have amino acid substitutions selected from, for example, the group consisting of: (A) E300A, (B) I240A and P241A, (C) E249Q, and (D) E300A and Y302A.

[0213] Acyl receptor probe Q

[0214] Acyl receptor probe Q is used in conjugation reactions to link linker-drug constructs with the structure AB-((L) 1 ) a Antibodies with -F)x. Q is reactive to acyl donor F in transglutaminase, particularly microbial transglutaminase-mediated transamidation. Such probes are known in the art, and the acyl acceptor commonly used in this reaction is a primary amine. However, recent studies have shown that other acyl acceptors containing a terminal -NH group, i.e., α-effect nucleophiles, such as hydrazides, acyl hydrazides, and alkoxyamines, can be used (Chio et al., 2020. Angew Chem Int Ed Engl 59(33): 13814-13820). Those skilled in the art will understand that the term 'α-effect' refers to the increased nucleophilicity of an atom due to the presence of an adjacent (α) atom with a lone pair of electrons; in this context, the increased nucleophilicity of the nitrogen atom of the terminal -NH of the acyl acceptor. In one embodiment, the acyl acceptor is selected from amines, such as primary amines; hydrazides; acyl hydrazides; alkoxyamines, or aryloxyamines. In another embodiment, the amine, hydrazine, acylhydrazine, or hydroxylamine is an aryl derivative, particularly a optionally substituted phenyl derivative or an optionally substituted benzyl derivative, such as an optionally substituted phenylhydrazine. In one embodiment, the acyl acceptor is a hydrazine or an acylhydrazine. In one embodiment, the acyl acceptor is an acylhydrazine or an optionally substituted arylhydrazine derivative. In yet another embodiment, the acyl acceptor is an optionally substituted phenylhydrazine or an optionally substituted phenylhydrazine derivative.

[0215] reactive group F

[0216] The reactive group F is a click probe, or a thiol or its precursor, or an acyl donor capable of reacting with the acyl acceptor probe Q in a microbial transglutaminase-mediated transamidation. Therefore, in the first embodiment, F is a click probe. The click probe F is used in a conjugation reaction to link a linker-drug construct to a modified antibody. F is reactive to the click probe Q in a metal-free click reaction. Such click probes are known in the art and include cyclic alkenes, cyclic alkynes, azides, tetrazides, triazines, nitrones, nitriles, nitriles, nitrile oxides, nitrile imides, diazo compounds, o-quinones, dioxothiophenes, and syldiones.

[0217] In particular, F is reactive to cyclic alkenes and cyclic alkynes, and is generally selected from the group consisting of: azides, tetrazides, triazines, nitrones, nitriles, nitriles, nitrile imines, diazo compounds, o-quinones, dioxothiophenes, and syldiones.

[0218] In particular, F is reactive to dienes (such as tetrazine, 1,2-quinone and triazine) and is usually selected from the group consisting of alkenyl and hydrocarbon groups, most particularly alkynyl or cycloalkenyl groups.

[0219] Specifically, the click probe F is selected from azides, tetrazides, and cycloalkenes. Most particularly, the click probe F is an azide.

[0220] In the second embodiment, F is a thiol or a precursor thereof. The thiol or its precursor F is used in the conjugation reaction to link the linker-drug construct to the modified antibody. F is reactive to the thiol-reactive probe Q in the thiol conjugation. In the case of bioconjugation, the thiol precursor is known in the art and includes disulfides, which can be naturally occurring disulfide bridges in the antibody or synthetically introduced disulfides that have been reduced as known in the art. Specifically, F is a thiol group.

[0221] In the third embodiment, F is an acyl donor. The acyl donor is used in the conjugation reaction to link the linker-drug construct to the modified antibody. F is reactive to the acyl receptor probe Q in transglutaminase-mediated transamidation, particularly microbial transglutaminase-mediated transamidation. F is an acyl derivative, particularly an amide or carboxylic acid derivative, and specifically, the acyl group is located in the side chain of an amino acid residue. Specifically, the amino acid is glutamine. Specifically, a is 0, and the amino acid, particularly glutamine, is located in antibody AB.

[0222] Linker-drug construct

[0223] In a third aspect, the present invention relates to a linker-drug construct according to structure (5). (5)

[0225] in: Q is a click probe capable of metal-free click reactions, or a thiol-reactive probe, or an acyl acceptor probe capable of reacting with acyl donor F in transglutaminase-mediated transamidation. L 2 L 3 D, n, b, and c are defined as above.

[0226] The linker-drug construct and L provided in the context of the first and second aspects of the present invention 2 L 3 The definitions and preferred embodiments of D, n, b, and c also apply to the third aspect of the invention. Linker-drug constructs according to this aspect are ideally suited as intermediates in the preparation of antibody-drug conjugates according to the invention. Therefore, the invention also relates to linker-drug constructs according to the invention and having the structure AB-((L1 The use of modified antibodies of )aF)x in metal-free click conjugation reactions, or thiol conjugation reactions, or transglutaminase, especially microbial transglutaminase-mediated transamidation conjugation reactions.

[0227] application

[0228] The present invention further relates to the use of the conjugates according to the invention in medicine.

[0229] In another aspect, the present invention provides a method for treating a subject in need, comprising administering the conjugate according to the invention to the subject.

[0230] On the other hand, the present invention provides conjugates according to the invention for treatment, particularly for treating subjects in need.

[0231] In another aspect, the present invention provides the use of the conjugates according to the invention in pharmaceutical manufacturing.

[0232] Application is usually performed with a therapeutically effective amount of the conjugate according to the invention.

[0233] The present invention further provides a method for treating a specific disease in a subject in need, comprising administering a conjugate according to the invention as defined above. Specifically, the specific disease may be selected from cancer and autoimmune diseases, particularly cancer. The subject in need is typically a cancer patient. The use of antibody-drug conjugates in such treatments is well known, particularly in the field of cancer treatment, and the conjugate according to the invention is particularly suitable in this regard. In the method according to this aspect, the conjugate is typically administered in a therapeutically effective amount.

[0234] On the other hand, the present invention provides conjugates according to the invention for treating specific diseases in subjects in need, particularly for treating cancer.

[0235] In another aspect, the present invention provides the use of the conjugates of the present invention in the preparation of pharmaceutical agents or pharmaceutical compositions for treating a specific disease in a subject in need, preferably for treating cancer.

[0236] In the context of this invention, administration refers to systemic administration. Therefore, in one embodiment, the method defined herein is used for systemic administration of the conjugate. Given the specificity of the conjugate, it can be administered systemically and still exert its activity in or near the tissue of interest (e.g., a tumor). Systemic administration has significant advantages over local administration because the drug can also reach tumor metastases that are undetectable by imaging techniques, and it can be applied to hematologic malignancies.

[0237] The present invention further provides a pharmaceutical composition comprising the antibody-capable conjugate of the present invention and a pharmaceutically acceptable carrier.

[0238] Some aspects and embodiments of this disclosure are described in more detail below with reference to the following examples, which are illustrative and not restrictive.

[0239] The example is illustrated in the following diagram: Figure 1 - A graph showing cLogP relative to the number of glycine or PEG units.

[0240] Example

[0241] Materials and methods

[0242] Preparation of drug linkers

[0243] Drug linker DL-A

[0244] Step 1: Alloc-Val-Ala-PABA (1) (29 g, 1 equivalent) was dissolved in MeCN (10 V). K₂CO₃ (2 equivalents) was added. The reaction mixture was heated to 50 °C. A solution of 4-nitrobenzene chloroformate in MeCN (2 equivalents at 5 V) was added. The reaction mixture was stirred at 50 °C for 6 hours. After completion, the reaction mixture was filtered. The filtrate was concentrated under vacuum to give a crude residue. The crude residue was purified by rapid column chromatography (silica) elution with EtOAc / DCM (0→20%) to give compound 2 (30 g, 72%).

[0245] Step 2: Exatecan mesylate (24 g, 1 equivalent) was dissolved in DMF (10 V). DIPEA (3 equivalents) was added. Compound 2 (1.25 equivalents) was added and the reaction mixture was stirred at 25 °C for 16 hours.

[0246] After completion, water (30 V) was added dropwise to the reaction mixture. The reaction mixture was stirred at 25 °C for 30 minutes. The reaction mixture was filtered, and the filter cake was washed with water (5 V), collected, and dried thoroughly to give compound 3 (29 g, 77%).

[0247] Step 3: Compound 3 (30 g, 1 equivalent) was dissolved in DCM (10 V). Pd(PPh3)4 (0.02 equivalent) and pyrrolidine (1.5 equivalent) were added. The reaction mixture was stirred at 25 °C for 2 hours. After completion, the reaction mixture was concentrated under vacuum to give a crude residue. The crude residue was purified by rapid column chromatography (silica) elution with MeOH / DCM (0→8%) to give compound 4 (17 g, 63%).

[0248] Step 4: Add 40 mL of saturated NaHCO3 solution to a solution of compound 5 (5.32 g, 20 mmol) and compound 6 (3.8 g, 20 mmol) in acetonitrile / water (1 / 2, v / v, 100 mL).

[0249] The reaction mixture was stirred at room temperature for 2 hours. Then, TFA (2.8 mL) was added and stirring was continued for another 10 minutes. The mixture was directly purified by preparative RP-HPLC to give compound 7 (6.1 g, 90%) as a white solid.

[0250] Step 5: PyAOP (2.13 g, 4.08 mmol) and DIPEA (2.1 mL, 12.08 mmol) were added to a solution of compound 4 (3.08 g, 4.08 mmol) and compound 8 (1.44 g, 4.08 mmol) in anhydrous DMF (50 mL). The reaction mixture was stirred at room temperature for 10 minutes. Then piperidine (2.0 mL) was added and stirring was continued for another 10 minutes.

[0251] The mixture was added to diethyl ether (500 mL) with stirring. The suspension was centrifuged and the precipitate was collected by decantation. The precipitate was then dissolved in 40 mL of DMF and purified by preparative RP-HPLC to give compound 9 (2.4 g, 60%) as a yellow solid TFA salt.

[0252] Step 6: AOP (367 mg, 0.83 mmol) and DIPEA (0.57 mL, 3.28 mmol) were added to a solution of compound 9 (TFA salt, 814 mg, 0.83 mmol) and compound 7 (282 mg, 0.83 mmol) in anhydrous DMF (20 mL). The reaction mixture was stirred at room temperature for 10 min. The mixture was then purified by preparative RP-HPLC to give compound DL-A (510 mg, 81%) as a yellow solid.

[0253] Preparative RP-HPLC method: Column: Phenomenex Gemini NX 5m, C18, 110 Å, 150 × 50 mm Instrument: Shimadzu LC with CTC IFC Mobile phase: A) Water (0.1% TFA), B) Acetonitrile Gradient: 10-65% B over 20 minutes, flow rate 50 mL / min

[0254] Analytical HPLC: Column: Phenomenex Gemini NX 5m, C18, 110 Å, 150 × 4.6 mm Instrument: Shimadzu LC-2030 Mobile phase: A) Water (0.05% TFA), B) Acetonitrile (0.05% TFA) Gradient: 20-70% B over 15 minutes, flow rate 1.0 mL / min 220 nm; 1191.6 [M+H+] All desired HPLC fractions were combined and lyophilized on a Virtis Freezemobile 35EL.

[0255] Drug linker DL-B

[0256] Step 1: Synthesize ((allyloxy)carbonyl)-glycyl-glycyl-glycine (22).

[0257]

[0258] Step 1 procedure: Alloc-Cl (7.65 g, 63.5 mmol, 1 equivalent) and NaHCO3 (7.11 g, 84.6 mmol, 2 equivalent) were added to a solution of compound 21 (8 g, 42.3 mmol, 1 equivalent) in THF / H2O (40 mL / 80 mL) under N2 protection at 30 ± 5 °C. The reaction mixture was stirred at 30 ± 5 °C for 2 h. The reaction was monitored by LCMS. The pH of the reaction solution was adjusted to 1 to 2. DCM (40 mL) was added to the reaction solution and the mixture was stirred for half an hour. After filtration and washing with DCM (40 mL), the desired product, compound 22 (11 g, 69%), was obtained as a solid.

[0259] 1 H NMR (400 MHz, DMSO- d 6) δ ppm 12.61 (s, 1H), 8.22 (dt, J = 12.3, 5.8Hz, 2H), 7.47 (t, J = 6.0 Hz, 1H), 5.91 (ddt, J = 17.2, 10.6, 5.3 Hz, 1H),5.30 (dq, J = 17.3, 1.8 Hz, 1H), 5.18 (dq, J = 10.5, 1.5 Hz, 1H), 4.49 (dt, J = 5.3, 1.6 Hz, 2H), 3.76 (t, J = 6.2 Hz, 4H), 3.67 (d, J = 6.1 Hz, 2H).

[0260] LCMS: (ES+) m / z = 274.2 [M+H] + At 1.25 min, the RT was 94.49%.

[0261] Step 2: Synthesis of ((allyloxy)carbonyl)-glycyl-glycyl-glycyl-glycyl-glycine methyl ester (23)

[0262] Step 2 procedure: SM3 (6.66 g, 36.60 mmol, 1 equivalent), DIEA (23.65 g, 183 mmol, 5 equivalent), and T3P (13.97 g, 43.92 mmol, 1.2 equivalent) were added to a solution of compound 22 (10 g, 36.60 mmol, 1 equivalent) in DMF (100 mL) under N2 protection at 0 ± 5 °C. The reaction mixture was stirred at 30 ± 5 °C for 2 h. The reaction was monitored by LCMS. H2O (300 mL) was added and the mixture was stirred for half an hour. After filtration and washing with H2O (50 mL), a wet filter cake was obtained. After drying at 40 °C, the desired product, compound 23 (11.5 g, 69%), was obtained as a grayish-white solid.

[0263] 1 H NMR (400 MHz, DMSO- d 6) δ 8.27 (t, J = 5.9 Hz, 1H), 8.16 (d, J = 9.4Hz, 3H), 7.44 (t, J = 6.0 Hz, 1H), 5.91 (ddt, J = 16.1, 10.6, 5.3 Hz, 1H),5.30 (dq, J = 17.1, 1.8 Hz, 1H), 5.18 (dd, J = 10.4, 1.8 Hz, 1H), 4.48 (dt, J = 5.3, 1.6 Hz, 2H), 3.85 (d, J = 5.8 Hz, 2H), 3.75 (dd, J = 5.8, 3.2 Hz, 6H), 3.65 (d, J = 15.1 Hz, 5H).

[0264] LCMS: (ES+) m / z = 402.10 [M+H] + At 0.42 min, the RT was 93.13%.

[0265] Step 3: Synthesis of (allyloxy)carbonyl)-glycyl-glycyl-glycyl-glycyl-glycine (24)

[0266] Step 3 procedure: LiOH (0.214 g, 8.97 mmol, 1.2 equivalent) was added to a mixture of compound 23 (3 g, 7.47 mmol, 1 equivalent) in MeOH / H2O (30 mL / 30 mL) under N2 protection at 0 ± 5 °C. The reaction mixture was stirred at 0 ± 5 °C for 6 h. The reaction was monitored by LCMS. The pH of the reaction solution was adjusted to 1 to 2, DCM (5 V) was added, and the mixture was stirred for half an hour. After filtration and washing with DCM (15 mL), a wet filter cake was obtained. After drying at 25 °C, the desired product, compound 24 (1.9 g, 66%), was obtained as a grayish-white solid.

[0267] 1 H NMR (400 MHz, DMSO- d 6) δ 8.16 (dq, J = 10.3, 6.2 Hz, 5H), 7.44 (t, J = 6.1 Hz, 1H), 5.91 (ddt, J = 16.2, 10.6, 5.3 Hz, 1H), 5.30 (dd, J = 17.3,1.9 Hz, 1H), 5.22 - 5.14 (m, 1H), 4.52 - 4.44 (m, 2H), 3.78 - 3.72 (m, 10H).

[0268] LCMS: (ES+) m / z = 388 [M+H] + At 0.94 min, the RT was 95.60%.

[0269] Step 4: Synthesis of ((R)-1-(((R)-1-((4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenyl)amino)-1-oxopropyl-2-yl)amino)-3-methyl-1-oxobut-2-yl)carbamate (26)

[0270] Step 4 procedure: Active ester 25 (5.07 g, 9.34 mmol, 1.25 equivalent) was added to a solution of ethatecan mesylate (4.5 g, 7.47 mmol, 1 equivalent) and DIEA (2.41 g, 18.68 mmol, 2.5 equivalent) in DMF (45 mL) under N2 protection at 30 ± 5 °C. The reaction mixture was stirred at 30 ± 5 °C for 2 h. The reaction was monitored by LCMS. H2O (135 mL) was added and the mixture was stirred for half an hour. After filtration and washing the filter cake with H2O (135 mL), a wet filter cake was obtained. After drying at 25 °C, the desired product, compound 26 (6 g, 69%), was obtained as a light brown solid.

[0271] LCMS: (ES+) m / z = 839.35 [M+H] + At 0.68 min, the RT was 93.99%.

[0272] Step 5: Synthesis of ((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)carbamate 4-((R)-2-((R)-2-amino-3-methylbutamido)propamido)benzyl ester (27)

[0273] Step 5 procedure: Pyrrolidine (0.763 g, 10.73 mmol, 1.5 equivalent) was added to a mixture of compound 26 (6 g, 7.15 mmol, 1 equivalent) and Pd(PPh3)4 (0.165 g, 0.143 mmol, 0.02 equivalent) in DCM (60 mL) under N2 protection at 30 ± 5 °C. The reaction mixture was stirred at 30 ± 5 °C for 2 h. The reaction was monitored by LCMS. After filtration and purification by silica gel column chromatography (DCM / MeOH), the desired product, compound 27 (4 g, 74%), was obtained as a pale brown solid.

[0274] 1 H NMR (300 MHz, DMSO- d 6) δ 10.08 (s, 1H), 8.43 (s, 5H), 8.04 (d, J =8.8 Hz, 1H), 7.63 (dd, J = 15.3, 9.6 Hz, 3H), 7.39 (d, J= 8.2 Hz, 2H), 7.28(s, 1H), 6.51 (s, 1H), 5.44 (s, 2H), 5.32 - 4.99 (m, 5H), 4.46 (d, J = 14.1Hz, 1H), 3.18 (s, 4H), 3.08 - 2.98 (m, 2H), 2.39 (td, J = 5.6, 4.3, 2.7 Hz,1H), 1.32 (d, J = 7.0 Hz, 3H), 0.85 (dd, J = 29.6, 6.9 Hz, 9H).

[0275] LCMS: (ES+) m / z = 755.35 [M+H] + At 0.525 min, the positivity rate was 99.81%. RT.

[0276] Step 6: Synthesis of ((16R,19R)-20-((4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenyl)amino)-16-isopropyl-19-methyl-2,5,8,11,14,17,20-heptaoxo-3,6,9,12,15,18-hexaazaeicosyl)carbamate (28)

[0277] Step 6 procedure: T3P (1.96 g, 6.16 mmol, 1 equivalent) and DIEA (0.796 g, 6.16 mmol, 1 equivalent) and compound 24 (2.07 g, 5.34 mmol, 1.3 equivalent) were added to a solution of compound 27 (3.1 g, 4.107 mmol, 1 equivalent) in DMF (31 mL) under N2 protection at 0 ± 5 °C. The reaction mixture was stirred at 30 ± 5 °C for 2 h. The reaction was monitored by LCMS. After filtration and purification by preparative HPLC (0.1% FA in H2O / ACN), the desired product, compound 28 (0.34 g, 7%), was obtained as a pale yellow solid.

[0278] 1 H NMR (400 MHz, DMSO-d 6) δ 9.94 (s, 1H), 8.26 (d, J J = 6.9 Hz, 1H),8.20 - 8.04 (m, 4H), 7.84 (d, J J = 8.8 Hz, 1H), 7.77 (d, J J = 10.9 Hz, 1H),7.60 (d, J J = 8.2 Hz, 2H), 7.44 (t, J J = 6.1 Hz, 1H), 7.37 (d, J J = 8.2 Hz, 2H),7.31 (s, 1H), 5.90 (ddt, J J = 16.1, 10.5, 5.3 Hz, 1H), 5.45 (s, 2H), 5.38 -5.13 (m, 5H), 5.08 (s, 2H), 4.47 (dt, J J = 5.3, 1.7 Hz, 2H), 4.37 (t, J J = 7.0Hz, 1H), 4.22 (dd, J J = 8.7, 6.7 Hz, 1H), 3.82 - 3.69 (m, 8H), 3.65 (d, J J =6.1 Hz, 5H), 2.37 (d, J J = 1.9 Hz, 3H), 2.16 (d, J J = 23.6 Hz, 2H), 2.03 - 1.80(m, 4H), 1.31 (d, J J = 7.1 Hz, 3H), 1.00 - 0.73 (m, 9H).

[0279] LCMS: (ES+) m / z = 1124.50 [M+H] + , at 0.80 min 93.57%. RT.

[0280] Step 7: Synthesis of ((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)carbamate 4-((2R,5R)-20-amino-5-isopropyl-2-methyl-4,7,10,13,16,19-hexaoxo-3,6,9,12,15,18-hexaazaeicosanoamide)benzyl ester (29)

[0281] Step 7 procedure: Pd(PPh3)4 (0.080 g, 0.06895 mmol, 0.25 equivalents) and PhSiH3 (0.447 g, 4.13 mmol, 15 equivalents) were added to a mixture of compound 28 (0.310 g, 0.2758 mmol, 1 equivalent) in DCM (31 mL) under N2 protection at 30 ± 5 °C. The reaction mixture was stirred in a microwave oven at 40 ± 5 °C for 0.5 h. The reaction was monitored by LCMS. After filtration and purification by preparative HPLC (0.05% TFA in H2O / ACN), the desired product, compound 29 (0.185 g, 65%), was given as a pale yellow solid.

[0282] 1 H NMR (400 MHz, DMSO- d 6) δ 9.94 (s, 1H), 8.21 - 8.04 (m, 4H), 7.87(t, J = 7.4 Hz, 2H), 7.71 (d, J = 7.5 Hz, 1H), 7.59 (dd, J = 7.3, 5.3 Hz,2H), 7.40 - 7.28 (m, 5H), 6.52 (s, 1H), 5.45 (s, 2H), 5.34 - 5.19 (m, 3H),5.08 (s, 2H), 4.38 (q, J = 7.1 Hz, 1H), 4.22 (t, J = 7.6 Hz, 2H), 3.75 (tt, J = 12.2, 5.2 Hz, 8H), 3.67 (d, J = 6.1 Hz, 2H), 3.22 (s, 2H), 3.10 (d,J =17.7 Hz, 1H), 2.54 (s, 1H), 2.37 (d, J = 1.9 Hz, 3H), 2.14 (d, J = 7.4 Hz,1H), 2.03 - 1.93 (m, 1H), 1.87 (dt, J = 16.7, 7.0 Hz, 2H), 1.30 (d, J = 7.1Hz, 3H), 0.92 - 0.79 (m, 9H).

[0283] LCMS: (ES+) m / z = 1040.45 [M+H] + At 0.72 min, the RT was 96.14%.

[0284] Step 8A: Synthesis of DBCO active ester

[0285] Step 8A procedure: NHS (0.090 g, 0.786 mmol, 1.2 equivalent) and DCC (0.162 g, 0.786 mmol, 1.2 equivalent) were added to a solution of DBCO acid (0.200 g, 0.655 mmol, 1 equivalent) in DCM (1 mL) under N2 protection at 20 ± 5 °C. The reaction mixture was stirred at 20 ± 5 °C for 1 hour. The reaction was monitored by LCMS. After concentration and purification by preparative HPLC (H2O / ACN), the desired product, DBCO active ester (110 mg, 42%), was obtained as a grayish-white solid.

[0286] LCMS: (ES+) m / z = 403.05 [M+H] + At 0.95 min, the result was 97.1%. RT.

[0287] Step 8: Synthesize DL-B

[0288] Step 8 procedure: DIEA (0.01 g, 0.07825 mmol, 2.2 equivalents) and DBCO active ester (0.0286 g, 0.07114 mmol, 2.0 equivalents) were added to a mixture of compound 29 (0.037 g, 0.03557 mmol, 1 equivalent) in DMF (1 mL) under N2 protection at 30 ± 5 °C. The reaction mixture was stirred at 30 ± 5 °C for 4 h. The reaction was monitored by LCMS. After filtration and purification by preparative HPLC (0.05% TFA in H2O / ACN), the desired product DL-B (3.9 mg, 8%) was given as a pale yellow solid. LCMS: (ES+) m / z = 1328.55 [M+H] + At 0.82 min, the RT was 85.0%.

[0289] Drug-linker DL-C

[0290] Synthetic compound 31

[0291] Step-1: Synthesis of 2-(4-(hydroxymethyl)-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-trimethyl ester of triacetic acid (31-1)

[0292] Step 1 procedure: Ag₂O (41.1 g, 177.4 mmol, 1.5 equivalent) was added to a solution of SM₁ (20 g, 118.2 mmol, 1 equivalent) and SM₂ (56.4 g, 141.9 mmol, 1.2 equivalent) in ACN (200 mL) under N₂ protection at 15 ± 5 °C. The reaction mixture was stirred at 15 ± 5 °C for 4 h. The reaction was monitored by LCMS. After filtration and purification by silica gel (acid) column chromatography (EtOAc / PE), the desired product 31-1 (35 g, 61%) was given as a grayish-white solid.

[0293] 1H NMR (300 MHz, DMSO- d 6) δ ppm 7.80 (d, J = 2.1 Hz, 1H), 7.62 (dd, J= 8.7, 2.1 Hz, 1H), 7.39 (d, J = 8.6 Hz, 1H), 5.72 (d, J = 7.8 Hz, 1H), 5.52- 5.39 (m, 2H), 5.17 - 5.06 (m, 2H), 4.75 (d, J = 9.9 Hz, 1H), 4.52 (d, J =5.6 Hz, 2H), 3.66 (s, 3H), 2.01 (d, J = 6.4 Hz, 9H).

[0294] LCMS: (ES+) m / z = 508 [M+Na] + At 1.89 min, the RT was 90.86%.

[0295] Step-2: Synthesis of 2-(4-(((tert-butyldimethylsilyl)oxy)methyl)-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-trimethyl ester of triacetic acid (31-2)

[0296] Step 2 procedure: Imidazole (7.4 g, 108.2 mmol, 1.5 equivalent) and TBSCl (12.0 g, 79.3 mmol, 1.1 equivalent) were added to a solution of 31-1 (35.0 g, 72.1 mmol, 1 equivalent) in DCM (350 mL) at 20 ± 5 °C under N2 protection. The reaction mixture was stirred at 20 ± 5 °C for 2 hours. The reaction was monitored by LCMS. The solution was then rinsed with pure water (350 mL). 2) After washing and drying with anhydrous NaSO4, the organic phase was concentrated to dryness. The desired product 31-2 (32 g, 74%) was obtained as a grayish-white solid.

[0297] 1 H NMR (400 MHz, DMSO- d 6) δ ppm 8.37 (s, 7H), 7.70 (d, J = 2.1 Hz, 1H), 7.53 (dd, J = 8.7, 2.2 Hz, 2H), 7.35 (d, J = 8.7 Hz, 1H), 5.67 (d, J =7.8 Hz, 1H), 5.38 (t,J = 9.5 Hz, 1H), 5.08 - 4.96 (m, 2H), 4.76 - 4.53 (m,3H), 3.56 (s, 3H), 2.10 - 1.78 (m, 9H), 0.81 (s, 8H), 0.08 - -0.22 (m, 6H).

[0298] LCMS: (ES+) m / z = 622.20 [M+Na] + At 3.18 min, the RT was 93.26%.

[0299] Step 3: Synthesis of 2-(2-amino-4-(((tert-butyldimethylsilyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-trimethyl ester of triacetic acid (31-3)

[0300] Step 3 procedure: Acetic acid (16 mL, 0.5 vol) was added to a mixture of 31-2 (32 g, 53.4 mmol, 1 equivalent) and Zn (4.0 g, 58.7 mmol, 1.1 equivalent) in MeOH / H2O (320 mL / 32 mL) under N2 protection at 15 ± 5 °C. The reaction mixture was stirred at 15 ± 5 °C for 2 h. The reaction was monitored by LCMS. After filtration and extraction with EtOAc and purification by silica gel (acid) column (EtOAc / PE), the desired product 31-3 (13 g, 43%) was given as a grayish-white solid.

[0301] 1H NMR (300 MHz, DMSO- d 6 ) δ ppm 6.83 (d, J = 8.2 Hz, 1H), 6.65 (d, J = 2.0 Hz, 1H), 6.46 (dd, J = 8.2, 2.0 Hz, 1H), 5.55 - 5.39 (m, 2H), 5.15 -5.02 (m, 2H), 4.71 - 4.60 (m, 3H), 4.53 (s, 2H), 3.66 (s, 3H), 2.07 - 1.99(m, 9H), 0.90 (s, 9H), 0.07 (s, 6H).

[0302] LCMS: (ES+) m / z = 570.4 [M+H] + At 2.75 min, the RT was 95.41%.

[0303] Step 4: Synthesis of 2-(2-(((allyloxy)carbonyl)amino)-4-(((tert-butyldimethylsilyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-trimethyl ester (31-4)

[0304] Step 4 procedure: AllocCl (2.8 g, 22.8 mmol, 1 equivalent) was added to a mixture of 31-3 (13 g, 22.8 mmol, 1 equivalent) and NaHCO3 (2.9 g, 34.2 mmol, 1.5 equivalent) in THF (90 mL) at 15 ± 5 °C under N2 protection. The reaction mixture was stirred at 15 ± 5 °C for 2 h. The reaction was monitored by LCMS. After filtration and extraction with EtOAc (130 mL), the desired product 31-4 (11.5 g, 77%) was given as a grayish-white solid.

[0305] 1H NMR (300 MHz, DMSO- d 6 ) δ ppm 8.12 (s, 1H), 7.69 (s, 1H), 7.12 -6.99 (m, 2H), 5.96 (ddd, J = 17.2, 10.5, 5.3 Hz, 1H), 5.58 - 5.33 (m, 3H), 5.26 - 5.03 (m, 3H), 4.73 - 4.56 (m, 5H), 3.65 (s, 3H), 2.07 - 1.98 (m, 9H), 0.91 (s, 9H), 0.08 (s, 6H).

[0306] LCMS: (ES+) m / z = 676.4 [M+Na] + At 3.22 min, the positivity rate was 91.34%. RT.

[0307] Step 5: Synthesis of 2-(2-(((allyloxy)carbonyl)amino)-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-trimethyl ester of triacetic acid (31-5)

[0308] Step 5 procedure: TEA (10.7 g, 105.5 mmol, 6.0 equivalent) was added to a solution of 31-4 (11.5 g, 17.6 mmol, 1 equivalent) and TEA.3HF (5.8 g, 35.2 mmol, 2.0 equivalent) in THF (115 mL) under N2 protection at 15 ± 5 °C. The reaction mixture was stirred at 15 ± 5 °C for 48 hours. The reaction was monitored by LCMS. The solution was then loaded with H2O (57.5 mL) and EtOAc (57.5 mL). 2) After extraction, the organic phase was concentrated to dryness. The desired product 31-5 (6.8 g, 72%) was obtained as a grayish-white solid.

[0309] 1H NMR (300 MHz, DMSO- d 6 ) δ ppm 8.14 (s, 1H), 7.67 (s, 1H), 7.10 -6.99 (m, 2H), 5.97 (ddt, J = 17.3, 10.6, 5.3 Hz, 1H), 5.57 - 5.50 (m, 1H),5.46 (d, J = 9.6 Hz, 1H), 5.38 (dq, J = 17.2, 1.7 Hz, 1H), 5.25 (q, J = 1.5Hz, 1H), 5.23 - 5.15 (m, 2H), 5.09 (t, J = 9.7 Hz, 1H), 4.70 (d, J = 9.9 Hz, 1H), 4.59 (dt, J = 5.3, 1.6 Hz, 2H), 4.42 (d, J = 5.6 Hz, 2H), 3.65 (s, 3H), 2.07 - 1.95 (m, 9H).

[0310] LCMS: (ES+) m / z = 562.2 [M+Na] + At 2.08 min, the RT was 90.50%.

[0311] Step-6: Synthesis of triacetic acid 2-(2-((((allyloxy)carbonyl)amino)-4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-trimethyl ester (31)

[0312] Step 6 procedure: DIEA (2.4 g, 18.9 mmol, 1.5 equivalent) was added to a solution of 31-5 (6.8 g, 12.6 mmol, 1 equivalent) and SM3 (4.6 g, 15.1 mmol, 1.2 equivalent) in DMF (68 mL) at 15 ± 5 °C under N2 protection. The reaction mixture was stirred at 15 ± 5 °C for 4 hours. The reaction was monitored by LCMS. The solution was then loaded with H2O (68 mL) and EtOAc (68 mL). 8) After extraction, the organic phase was rinsed with water (68 mL). 4) Wash to remove residual DMF. After purification by silica gel (acid) column (EtOAc / PE), the desired product 31 (3.3 g, 37%) was obtained as a grayish-white solid.

[0313] 1H NMR (300 MHz, DMSO- d 6 ) δ ppm 8.37 - 8.26 (m, 3H), 7.83 (s, 1H), 7.63 - 7.54 (m, 2H), 7.23 (dd, J = 8.4, 2.0 Hz, 1H), 7.16 (d, J = 8.5 Hz,1H), 6.06 - 5.90 (m, 1H), 5.63 (d, J = 7.7 Hz, 1H), 5.49 (t, J = 9.6 Hz, 1H), 5.39 (dq, J = 17.2, 1.7 Hz, 1H), 5.28 - 5.12 (m, 4H), 4.73 (d, J = 9.9 Hz, 1H), 4.61 (dt, J = 5.4, 1.5 Hz, 2H), 3.65 (d, J = 1.3 Hz, 3H), 2.08 - 1.97(m, 9H).

[0314] LCMS: (ES+) m / z = 727.6 [M+Na] + At 2.76 min, the RT was 94.37%.

[0315] Step-1: Synthesis of triacetic acid (2S,3R,4S,5S,6S)-2-(2-((((allyloxy)carbonyl)amino)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl ester (32)

[0316] Step 1 procedure: DIEA (2.9 g, 22.7 mmol, 2.0 equivalent) and ethatecan mesylate (6.0 g, 11.4 mmol, 1 equivalent) were added to a solution of compound 31 (8 g, 11.4 mmol, 1 equivalent) in DMF (160 mL) under N2 protection at 20 ± 5 °C. The reaction mixture was stirred at 20 ± 5 °C for 16 h. The reaction was monitored by LCMS. After extraction with H2O (160 mL) and EtOAc (160 mL), the organic phase was washed with water (80 mL). The organic phase was dried over Na2SO4 and concentrated to dryness, then slurried with MTBE (40 mL) to give the desired product 32 (9 g, 79%) as a grayish-white solid.

[0317] LCMS: (ES+) m / z = 1001.30 [M+H] + At 4.06 min, the RT was 82.53%.

[0318] Step 2: Synthesis of triacetic acid (2S,3R,4S,5S,6S)-2-(2-amino-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-trimethyl ester (33)

[0319] Step 2 procedure: Pyrrolidine (0.96 g, 13.5 mmol, 1.5 equivalent) and Pd(PPh3)4 (0.21 g, 0.18 mmol, 0.02 equivalent) were added to a mixture of compound 32 (9 g, 9.0 mmol, 1 equivalent) in DMF (180 mL) under N2 protection at 20 ± 5 °C. The reaction mixture was stirred at 20 ± 5 °C for 12 h. The reaction was monitored by LCMS. The reactants were quenched with H2O (90 mL). The organic phase was dried over Na2SO4 and concentrated to dryness. After purification by preparative HPLC (0.05% TFA, ACN) and lyophilization, the desired product 33 (3.1 g, 37%) was given as a white solid.

[0320] LCMS: (ES+) m / z = 917.2 [M+H] + At 3.67 min, the RT was 94.00%.

[0321] Step 3: Synthesis of triacetic acid (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluoren-9-yl)-3,6,9,12,15-pentoxo-2-oxa-4,7,10,13,16-pentazaoctadecane-18-amido)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl ester (35)

[0322] Step 3 procedure: DIEA (0.34 g, 2.6 mmol, 1.2 equivalent) and HATU (1.00 g, 2.6 mmol, 1.2 equivalent) were added to a mixture of compound 34 ([see step 3A], 1.26 g, 2.4 mmol, 1.1 equivalent) in DMF (40 mL) under N2 protection at 20 ± 5 °C. The reaction mixture was stirred at 20 ± 5 °C for 0.5 h. Compound 33 (2.0 g, 2.2 mmol, 1.0 equivalent) was added to the mixture. The reaction mixture was stirred at 20 ± 5 °C for 16 h. The reaction was monitored by LCMS. DMSO (60 mL) was added to the reaction mixture. After purification by preparative HPLC (0.05% TFA, MeOH) and lyophilization, the desired product 35 (1.3 g, 41%) was obtained as a white solid.

[0323] LCMS: (ES+) m / z = 712.8 [1 / 2M+H] + At 3.79 min, the RT was 95.69%.

[0324] Step 3A:

[0325] Step 4: Synthesis of triacetic acid (2S,3R,4S,5S,6S)-2-(2-(14-amino-4,7,10,13-tetraoxo-3,6,9,12-tetraazatetradecanoamide)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-trimethyl ester (36)

[0326] Step 4 procedure: Piperidine (12.6 mg, 0.15 mmol, 0.7 equivalent) was added to a mixture of compound 35 (300 mg, 0.21 mmol, 1.0 equivalent) in DMF (40 mL) under N2 protection at 20 ± 5 °C. The reaction mixture was stirred at 20 ± 5 °C for 3 h. The reaction was monitored by LCMS. DMSO (6 mL) was added to the reaction mixture. After purification by preparative HPLC (0.05% TFA, MeOH) and lyophilization, the desired product 36 (100 mg, 39%) was given as a white solid.

[0327] LCMS: (ES+) m / z = 1202.4 [M+H] + At 3.17 min, the positivity rate was 89.83%. RT.

[0328] Step 5: Synthesis of ((2S,3S,4S,5R,6S)-6-(2-(14-amino-4,7,10,13-tetraoxo-3,6,9,12-tetraazatetradecanoamide)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (37)

[0329] Step 5 procedure: K₂CO₃ (57.49 mg, 0.416 mmol, 5.0 equivalent) was added to a mixture of compound 36 (100 mg, 0.083 mmol, 1.0 equivalent) in MeOH / H₂O (1 mL / 1 mL) under N₂ protection at 20 ± 5 °C. The reaction mixture was stirred at 20 ± 5 °C for 16 h. The reaction was monitored by LCMS. The pH of the reaction mixture was adjusted to 4 to 6 with 2 M HCl. After lyophilization, the desired product 37 (80 mg, 91%) was obtained as a white solid.

[0330] LCMS: (ES+) m / z = 1424.46 [M+H] + At 2.75 min, the RT was 70.69%.

[0331] Step 6: Synthesis of (2S,3S,4S,5R,6S)-6-(2-(18-(2,5-dioxo-2,5-dihydro-1H-pyrrolo-1-yl)-4,7,10,13,16-pentoxo-3,6,9,12,15-pentazaoctadecanoamide)-4-(((((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)carbamoyl)oxy)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (DL-C)

[0332] Step 6 procedure: DIEA (15.21 mg, 0.118 mmol, 1.0 equivalent) and compound 38 (31.33 mg, 0.118 mmol, 1.0 equivalent) were added to a mixture of compound 37 (125 mg, 0.118 mmol, 1.0 equivalent) and DMF (2.5 mL) under N2 protection at 20 ± 5 °C. The reaction mixture was stirred at 20 ± 5 °C for 2 h. The reaction was monitored by LCMS. The pH of the reaction mixture was adjusted to 5 to 6 with 0.5 M HCl. After purification by preparative HPLC (0.05% TFA, MeOH) and lyophilization, the desired product DL-C (20 mg, 14%) was obtained as a pale yellow solid.

[0333] LCMS: (ES+) m / z = 1213.4 [M+H] + At 2.82 min, the RT was 91.82%.

[0334] Drug linker DL-D

[0335] Synthesis of Compound 41

[0336] Synthesis of (3-(2,5-dioxo-2,5-dihydro-1H-pyrrolo-1-yl)propionyl)glycylglycylglycylglycyl-L-valine-L-alanine (41)

[0337] Step 1-1 procedure: DMF (300 mL) and CTC-resin (20.0 g, 1.6 mmol / g, 32.0 mmol, 1.0 equivalent) were added to SPPS reactor A at 25 ± 5 °C. The mixture was bubbled with nitrogen and swollen for 1 hour. SM1-1 (39.4 g, 96.0 mmol, 3.0 equivalent) and DIEA (20.7 g, 160.0 mmol, 5.0 equivalent) were added to the mixture. The mixture was bubbled with nitrogen for 1.5 hours. The reaction was monitored by LCMS. The mixture was filtered and saturated with DMF (200 mL). 3) Wash.

[0338] Procedure for steps 1-2: Add piperidine / DMF solution (200 mL, 20 v / v%) to SPPS reactor A at room temperature. Bubble the reaction mixture with nitrogen for 40 minutes. Monitor the reaction by LCMS (following the sampling procedure as described above). Wash the mixture with DMF (200 mL) until the pH reaches approximately 7. Add SM1-2 (19.7 g, 48.0 mmol, 1.5 equivalent), HOBT (6.5 g, 48.0 mmol, 1.5 equivalent), DIEA (6.2 g, 48.0 mmol, 1.5 equivalent), and DMF (300 mL) to SPPS reactor B. Cool the reaction system to 0°C and add HATU (18.3 g, 48.0 mmol, 1.5 equivalent). Stir the reaction mixture for 10 minutes and then transfer it to SPPS reactor A. Bubble the reaction mixture with nitrogen for 1.5 hours. Monitor the reaction by LCMS (following the sampling procedure as described above). Filter the mixture and wash with DMF (200 mL). 3) Wash.

[0339] Procedures for steps 1-3: Add piperidine / DMF solution (200 mL, 20 v / v%) to SPPS reactor A at room temperature. Bubble the reaction mixture with nitrogen for 40 minutes. Monitor the reaction by LCMS (following the sampling procedure as described above). Wash the mixture with DMF (200 mL) until the pH reaches approximately 7. Add SM1-3 (17.0 g, 48.0 mmol, 1.5 equivalent), HOBT (6.5 g, 48.0 mmol, 1.5 equivalent), DIEA (6.2 g, 48.0 mmol, 1.5 equivalent), and DMF (300 mL) to SPPS reactor B. Cool the reaction system to 0°C and add HATU (18.3 g, 48.0 mmol, 1.5 equivalent). Stir the reaction mixture for 10 minutes and then transfer it to SPPS reactor A. Bubble the reaction mixture with nitrogen for 1.5 hours. Monitor the reaction by LCMS (following the sampling procedure as described above). Filter the mixture and wash with DMF (200 mL). 3) Wash.

[0340] Procedures for steps 1-4: Add piperidine / DMF solution (200 mL, 20 v / v%) to SPPS reactor A at room temperature. Bubble the reaction mixture with nitrogen for 40 minutes. Monitor the reaction by LCMS (following the sampling procedure as described above). Wash the mixture with DMF (200 mL) until the pH reaches approximately 7. Add SM1-4 (8.1 g, 48.0 mmol, 1.5 equivalent), HOBT (6.5 g, 48.0 mmol, 1.5 equivalent), DIEA (6.2 g, 48.0 mmol, 1.5 equivalent), and DMF (300 mL) to SPPS reactor B. Cool the reaction system to 0°C and add HATU (18.3 g, 48.0 mmol, 1.5 equivalent). Stir the reaction mixture for 10 minutes and then transfer it to SPPS reactor A. Bubble the reaction mixture with nitrogen for 1.5 hours. Monitor the reaction by LCMS (following the sampling procedure as described above). Filter the mixture and wash with DMF (200 mL). 3) Wash.

[0341] Procedures for steps 1-5: Use DCM (200 mL) 4) Wash the filter cake. Add TFE / DCM solution (300 mL, 20 v / v%) to SPPS reactor A. Bubble the mixture with nitrogen and pyrolyze for 2 hours. After filtration and concentration, slurry with MTBE (600 mL). Obtain the desired product 41 (7 g, 37%) as a yellow solid.

[0342] LCMS: (ES+) m / z = 625.25 [M+H] + At 0.43 min, the RT was 93.11%.

[0343] Synthesis of (S)-2-(18-(2,5-dioxo-2,5-dihydro-1H-pyrrolo-1-yl)-4,7,10,13,16-pentoxo-3,6,9,12,15-pentazaoctadecanoamide)-N-((S)-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)amino)-1-oxopropyl-2-yl)-3-methylbutyramide (DL-D)

[0344] Step 2 procedure: HATU (30 mg, 0.10 mmol, 1.2 equivalent), DIEA (31 mg, 0.24 mmol, 3.0 equivalent), and EM (43 mg, 0.08 mmol, 1.0 equivalent) were added to a reactor at 20 ± 5 °C to a mixture of compound 41 (50 mg, 0.08 mmol, 1.0 equivalent) in DMF (1 mL). The reaction mixture was stirred at 20 ± 5 °C for 4 h. The reaction was monitored by LCMS. The product was separated and purified by preparative HPLC (0.05% TFA in water, ACN). After lyophilization, the desired product DL-D (18 mg, 22%) was obtained as a yellow solid.

[0345] 1 H NMR (300 MHz, DMSO- d 6) δ 8.44 (d, J = 8.6 Hz, 1H), 8.26 (t, J = 5.8Hz, 1H), 8.11 (ddt, J = 20.3, 11.5, 6.4 Hz, 6H), 7.80 (dd, J = 9.9, 6.8 Hz,2H), 7.30 (s, 1H), 5.54 (dd, J = 9.1, 4.5 Hz, 1H), 5.42 (s, 2H), 5.22 - 5.06(m, 2H), 4.26 (q, J = 6.9 Hz, 1H), 4.17 (dd, J = 8.7, 6.7 Hz, 1H), 3.73 (t, J = 5.9 Hz, 9H), 3.60 (d, J = 1.8 Hz, 2H), 3.17 (s, 2H), 2.42 - 2.37 (m, 4H), 2.13 (s, 2H), 1.89 (dt, J = 19.1, 6.6 Hz, 3H), 1.30 - 1.23 (m, 5H), 0.88 -0.77 (m, 9H).

[0346] LCMS: (ES+) m / z = 1042.40 [M+H] + At 1.09 min, the RT was 98.00%.

[0347] Synthetic linker LN-B

[0348] ADC Synthesis

[0349] ADC-A: DL-A conjugation

[0350] The test ADC has essanotecan as the warhead and maleimide-Gly5 (or Gly3)-Val-Ala-PABA linker (DL-A) conjugated to the test monoclonal antibody via cysteine ​​residues in the hinge region, essentially as described in Zammarchi et al., 2016. Mol Cancer Ther 15: 2709. Briefly, the antibody was buffer-exchanged to histidine buffer at pH 6 using tangential flow filtration, the pH was adjusted to 7.5 using TRIS / EDTA pH 8.5 buffer, and the solution was reduced with tris(2-carboxyethyl)phosphine reducing agent (TCEP). Dimethylacetamide and the drug-linker (three times the excess relative to the antibody) were added to the solution. The conjugated reaction was incubated, then quenched with three times the molar excess of N-acetylcysteine, and incubated again. The pH was then lowered to 6.0 using histidine hydrochloride solution, and the resulting ADC was purified by tangential flow filtration, filtered, and stored at -70°C. The final yield was estimated by UV-Vis spectrophotometry based on the starting antibody. The synthesis of the drug linker DL-A was described above.

[0351] ADC-B: MTGase mediates the conjugation of LN-B to mAbA, followed by conjugation to the drug linker DL-B.

[0352] MAbA (91.6 mg, 2.58 mL) was diluted with PBS (91.6 mL) at pH 7.2. 5.3 mg / mL EndoS solution (69.1 μL, 0.4% w / w), 6.7 mg / mL mTGase solution (2.03 mL, 6 U / mg), and 10 mM Ln-B (5.37 mg, 1.27 mL, 20 equivalents) were added to the diluted antibody. The resulting reaction mixture was then incubated overnight at 37°C. The crude conjugate was purified by protein A chromatography (MabSelect SuRu). The concentration of purified mAbA-In-B was determined by UV-A280 (4.12 mg / mL). PBS (114.0 μL) and propylene glycol (50.0 μL) were added to mAbA-In-B (0.25 mg, 61.0 μL), followed by 10 mM DL-B (22.8 μg, 0.86 μL, 10 equivalents) and DMA (25.0 μL). The conjugation mixture was mixed and incubated overnight at 22 °C. The final conjugation reaction was analyzed by SEC (98.9% monomer), HIC (DAR 1.9), and RP (DAR 1.8).

[0353] ADC-C: Conjugation of DL-C and mAbB

[0354] Add 500 mM Tris, pH 8 (25 mM EDTA) (150 μL) to mAbB (15 mg, 3.0 mL). Mix the resulting solution and then add 50 mM TCEP (14.5 μL, 7.0 equivalence). Mix the reduced reaction mixture and incubate at 22 °C for 1.5 h. Add DMSO (1.01 mg, 83.0 μL, 8.5 equivalence) and DMSO (268.6 μL) containing 10 mM DL-C to the reduced antibody solution (15 mg, 3.16 mL). Mix the resulting conjugated reaction mixture and incubate at 22 °C for 1 h. After 1 h of conjugation, add an additional 10 mM DL-C (0.25 mg, 20.8 µL, 2.0 equivalence), mix the reaction mixture, and continue the reaction for another 1 h. Analyze the final conjugation reaction by SEC (94.2% monomer) and HIC (DAR 6.0).

[0355] ADC-D: Conjugation of DL-D and mAbC

[0356] Add 500 mM Tris, pH 8 (25 mM EDTA) (250 µL) to mAbC (30 mg, 5.0 mL). Mix the resulting solution and then add 50 mM TCEP (26.7 μL, 6.5 equivalents). Mix the reduction reaction mixture and incubate at 22 °C for 1.5 h. Add DMSO (1.93 mg, 185 μL, 9.0 equivalents) and DMSO (401 μL) containing 10 mM DL-D to the reduced antibody solution (30 mg, 5.28 mL). Mix the resulting conjugation reaction mixture and incubate at 22 °C for 1 h. Analyze the conjugation reaction by SEC (98.8% monomer), HIC (DAR 6.0), and RP (DAR 6.0).

[0357] mAbA, mAbB, and mAbC each target different antigens. mAbA is a wild-type antibody. mAbB and mAbC contain a C228V mutation and only one heavy chain disulfide bond.

[0358] Clustering Research

[0359] Two mg (8.87 mg / mL) of the test monoclonal antibody was pH-adjusted with 5% 0.5 M Tris and 0.025 M EDTA (pH 8.5), reduced with 2.3 molar equivalents of TCEP, and then conjugated with 6 molar equivalents of the drug linker. After exchanging the buffer for 30 mM histidine, 175 mM sucrose, pH 6.0 / PBS, the drug-to-antibody ratio (DAR) was determined by HIC / LC-MS, and the monomer percentage was determined by size exclusion chromatography (SEC). A monomer percentage of 95% or higher was assessed as low aggregation.

[0360] Example 1 - Aggregation Study Using Exatecan Connectors

[0361] Previous studies using PEG-based linkers and esxatecan warheads have shown poor aggregation properties. Therefore, an alternative linker design was sought. A novel linker was designed using multiple glycine residues instead of PEG, which improved the aggregation level (data not shown). This glycine linker concept was subsequently tested in a novel construct based on a maleimide conjugate and a Val-Ala-PABC cleavable moiety linked to esxatecan.

[0362] The maleimide-Gly3-Val-Ala-PABC-ethanotecan construct was compared with the maleimide-Gly5-Val-Ala-PABC-ethanotecan construct (DL-A, whose synthesis is described above, with the Gly3 variant differing only in the number of Gly residues). LogP values ​​(a measure of hydrophobicity) were estimated using CDD Vault software (Collaborative Drug Discovery Inc.) based on the method described in Gedeck et al., 2017, J. Chem. Inf. Model. 57, 8, 1847-1858. Model training information using publicly available datasets was obtained from CDD. The results are shown in Table 1.

[0363] Correlation studies were also performed using reversed-phase HPLC (RP-HPLC). Two constructs were injected into the RP-HPLC, and retention time (Rt) was correlated with hydrophobicity—that is, high Rt was associated with the hydrophobic construct, while low Rt was associated with the hydrophilic construct. The results are shown in Table 1.

[0364] Assess and test the level of aggregation during antibody conjugation.

[0365] During conjugation, the ideal target is a monomer content or monomer percentage of 95% or higher. A low monomer percentage generally indicates a higher degree of aggregation. Therefore, a monomer percentage of 95% or higher can be considered to mean a very low or no aggregation level, while values ​​below this threshold generally indicate a high aggregation level.

[0366] result

[0367] Table 1

[0368] discuss

[0369] These results clearly demonstrate that the novel pentaglycine spacer / linker drug linker construct possesses enhanced hydrophilicity. The incorporation of this Gly5 motif results in increased hydrophilicity and lower aggregation levels in the construct, thus achieving an optimal conjugation process. The Gly5-based construct showed no aggregation, while the Gly3-based form exhibited moderate aggregation.

[0370] Example 2 - Comparison of cLogP values ​​for different polyglycine and PEG linkers.

[0371] The cLogP values ​​were calculated as described above for polyglycine and polyethylene glycol (PEG) linkers with lengths of 5 to 8, having two different conjugating groups (maleimide (Mal) and dibenzocyclooctyne (DBCO)). PEG is commonly used in linkers to enhance hydrophilicity. The values ​​are shown in Table 2 below.

[0372] Table 2

[0373] These results are plotted on Figure 1 It is readily apparent that, for the same number of units, glycine results in a lower cLogP. Furthermore, the effect of glycine on reducing cLogP is stronger with each additional unit.

[0374] Example 3 - Conjugation Study Using Exanotecan Linkers - PEG and Glycine

[0375] Mal-Gly5-VA-PABC-ethanotecan (DL-A) and one variant (using PEG5 instead of Gly5) both conjugated essentially to the same test antibody as described in Example 1, but with different cysteine ​​mutations, resulting in different target maximum drug-to-antibody ratios (DARs)—(4, 6, or 8). The degree of conjugation was determined by analysis of the conjugates using HIC-UHPLC (TSKgel Butyl-NPR column) and PLRP-HPLC (MAbPAC RP).

[0376] result

[0377] Table 3

[0378] in conclusion: The Gly5 type results in a much better conjugation spectrum than the PEG5 type.

[0379]

[0380] Numerous publications have been cited above to more fully describe and disclose the disclosures and prior art that may be involved in the invention herein. The entire contents of each reference mentioned in this disclosure are hereby incorporated by reference.

Claims

1. An antibody-drug conjugate having the structure (1) (1) in: AB is a cell-binding agent, such as an antibody; n is an integer in the range of 5 to 8; L 1 For connectors; L 2 For connectors; L 3 For connectors; a, b, and c are independently 0 or 1; Z is a linker group obtained by metal-free click reaction, thiol bonding, or transglutaminase-mediated transamidation. Or Z is absent, where a and b are 0, and the N-terminus of polyglycine is directly bonded to AB in the absence of a sorting enzyme recognition sequence motif; D is the effective drug load. x is an integer in the range of 1 to 8.

2. The antibody-drug conjugate of claim 1, wherein D is ethathecan, optionally wherein the drug linker is capable of cleavage under cellular conditions to release a drug having the following formula (D 1 Isanotecan: (D 1 ) 。 3. The antibody-drug conjugate according to claim 1 or 2, wherein L 3 It contains cathepsin-cleavable peptides or pod protein-cleavable peptides.

4. The antibody-drug conjugate according to any of the preceding claims, wherein L 3 for , The antibody-drug conjugate has structure (1a). (1a) in: AB is a cell-binding agent, such as an antibody; n is an integer in the range of 5 to 8; L 1 For connectors; L 2 For connectors; L 3a For connectors; a, b, and d are independently 0 or 1; Z is a linker group obtained by metal-free click reaction, thiol bonding, or transglutaminase-mediated transamidation. Or Z is absent, where a and b are 0, and the N-terminus of polyglycine is directly conjugated to AB in the absence of a sorting enzyme recognition sequence motif; D represents the effective drug load; p is an integer in the range of 1 to 5; Each R 11 Independent of amino acid side chains; x is an integer in the range of 1 to 8.

5. The antibody-drug conjugate according to any of the preceding claims, wherein L 3 It contains self-sacrificing groups.

6. The antibody-drug conjugate according to claim 4 or 5, having structure (1b). (1b) in: AB is a cell-binding agent, such as an antibody; n is an integer in the range of 5 to 8; L 1 For connectors; L 2 For connectors; a and b are independently 0 or 1; Z is a linker group obtained by metal-free click reaction, thiol bonding, or transglutaminase-mediated transamidation. Or Z is absent, where a and b are 0, and the N-terminus of polyglycine is directly bonded to AB in the absence of a sorting enzyme recognition sequence motif; D represents the effective drug load; p is an integer in the range of 0 to 5; Each R 11 Independent of amino acid side chains; A is an optionally substituted 5- or 6-membered aromatic ring or heteroaromatic ring; R 21 Selected from H, R 22 C(O)OH and C(O)R 22 , where R 22 For C1-C 24 (Hetero)alkyl, C3-C 10 (Hetero)cycloalkyl, C2-C 10 (Miscellaneous) aryl, C3-C 10 Alkyl (hetero)aryl and C3-C 10 (Hetero)arylalkyl, optionally composed of one or more elements selected from O, S, and NR. 23 The heteroatom is substituted and optionally interdoped with the heteroatom, wherein R 23 Independently selected from the group consisting of hydrogen and C1-C4 alkyl groups, x is an integer in the range of 1 to 8.

7. The antibody-drug conjugate according to any of the preceding claims, wherein the peptide (NH-CR) 11 -CO)p is selected from Val-Cit, Glu-Val-Cit, Val-Ala, Val-Lys, Val-Arg, Aclys-Val-Cit, Aclys-Val-Ala, Glu-Val-Ala, Asp-Val-Ala, Phe-Gly, Phe-Cit, Phe-Ala, Phe-Lys, Phe-Arg, Ala-Lys, Leu-Cit, Ile-Cit, Trp-Cit, Ala-Ala-Asn, Asn-Asn, Ala-Asn, and Lys, optionally selected from Val-Cit, Glu-Val-Cit, Val-Ala, Glu-Val-Ala, Val-Lys, and Phe-Gly. Phe-Cit, Phe-Ala, Phe-Lys, and Ala-Ala-Asn are optionally Val-Cit or Val-Ala.

8. The antibody-drug conjugate according to any of the preceding claims, wherein the linker group Z is obtainable by a metal-free click reaction and comprises a triazole moiety; or group Z is obtainable by thiol conjugation and comprises a succinimide ring or an open-ring succinamide derivative thereof.

9. The antibody-drug conjugate according to any of the preceding claims, having structure (1c). (1c) Z, L 2 L 3 D, b, c, n, and x are as defined in any of the preceding claims; e is an integer in the range of 0 to 20; Su is a monosaccharide; G is a monosaccharide fraction; GlcNAc is the N-acetylglucosamine moiety; Fuc is a fucose fraction; m is 0 or 1.

10. The antibody-drug conjugate according to any of the preceding claims, wherein L 2 It does not contain (poly) glycol linkers.

11. The antibody-drug conjugate according to any of the preceding claims, wherein L 2 Selected from -(CR) 1 R 2 )y-、-(CR 1 R 2 )yC(O)- and -C(O)-(CR 1 R 2 )yC(O)-, where y is an integer in the range of 0 to 6, and one or more CR 1 R 2 Can be arbitrarily NR 1 Substitution; R 1 and R 2 Independently selected from H and R 2a C(O)OH and C(O)R 2a , where R 2a Selected from optionally substituted C1-C6 (hetero)alkyl, C3-C 10 (Hetero)cycloalkyl, C6-C 10 (Miscellaneous) aryl, C7-C 14 Alkyl (hetero)aryl and C7-C 14 (Hetero)arylalkyl.

12. A method for synthesizing an antibody-drug conjugate according to any one of claims 1 to 11, comprising making... (i) has the structure AB-((L 1 ) a -F)x modified antibodies, where: AB is a cell-binding agent, such as an antibody; L 1 For connectors; a is 0 or 1; F is a click probe that can react with Q in a metal-free click reaction, or a thiol or its precursor, or an acyl donor that can react with Q in transglutaminase-mediated transamidation. x is an integer in the range of 1 to 8; and Based on the linker-drug construct of structure (5): in: Q is a click probe capable of metal-free click reactions, or a thiol-reactive probe, or an acyl acceptor probe capable of reacting with acyl donor F in transglutaminase-mediated transamidation. L 2 L 3 D, n, b and c are as defined in any of the preceding claims; The reaction is carried out to form an antibody-drug conjugate, wherein the drug is covalently linked to the antibody via a linker group Z, which is formed by a metal-free click reaction between Q and F, or by thiol bonding between Q and F, or by transglutaminase-mediated transamidation between Q and F.

13. The method of claim 12, wherein the click probe Q comprises a cycloalkyne moiety, a cycloolefin moiety, or a tetrazine moiety.

14. The method of claim 12, wherein the thiol reactive probe Q comprises or is a maleimide portion.

15. The method according to any one of claims 12 to 14, wherein the click probe F is selected from the group consisting of: azides, tetrazides, triazines, nitrones, nitriles, nitriles, nitrile imides, diazo compounds, o-quinones, dioxothiophenes, sylenes, alkynes, and cycloalkenes, wherein the click probe F is preferably an azide moiety; and / or wherein the click reaction is a 1,3-dipolar cycloaddition or a (4+2) cycloaddition; or F is a thiol; and / or wherein the thiol conjugation is a Michael addition or nucleophilic substitution.

16. The method according to any one of claims 12 to 15, wherein AB-((L 1 )aF)x is based on structure (6): (6) Wherein F and x are as defined in any of the preceding claims; e is an integer in the range of 0 to 10; Su is a monosaccharide; G is a monosaccharide fraction; GlcNAc is the N-acetylglucosamine moiety; Fuc is a fucose fraction; m is 0 or 1.

17. A linker-drug construct based on structure (5): (5) in: Q is a click probe capable of metal-free click reactions, or a thiol-reactive probe, or an acyl acceptor probe capable of reacting with acyl donor F in transglutaminase-mediated transamidation. L 2 L 3 D, n, b, and c are as defined in any of the preceding claims.

18. The linker-drug construct of claim 17, wherein the click probe Q comprises a cycloalkyne moiety, a cycloolefin moiety, or a tetrazine moiety.

19. The linker-drug construct of claim 17, wherein the thiol reactive probe Q comprises or is a maleimide moiety.

20. A pharmaceutical composition comprising an antibody-drug conjugate according to any one of claims 1 to 11 and a pharmaceutically acceptable carrier.

21. The antibody-drug conjugate according to any one of claims 1 to 11, for use in treating a subject in need.